

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Diabetes Mellitus and Its Associated Factors among Tuberculosis Patients Attending Directly Observed Treatment Centres in Oyo State, Nigeria: A cross sectional evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059260
Article Type:	Original research
Date Submitted by the Author:	12-Nov-2021
Complete List of Authors:	Anyanwu, Maureen; Nigeria Field Epidemiology and Laboratory Training Program Ajumobi, Olufemi; Nigeria Field Epidemiology and Laboratory Training Programme; University of Nevada Reno School of Community Health Sciences Afolabi, Nathanael; University of Ibadan, Department of Epidemiology and Medical Statistics Usman, Aishat; Nigeria Field Epidemiology and Laboratory Training Programme, NFELTP Kehinde, Aderemi; College of Medicine, University of Ibadan, Department of Medical Microbiology and Parasitology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Tuberculosis < INFECTIOUS DISEASES, Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Diabetes Mellitus and Its Associated Factors among Tuberculosis Patients Attending Directly Observed Treatment Centres in Oyo State, Nigeria: A cross sectional evaluation

Maureen O. Anyanwu^{1*}, Olufemi O. Ajumobi^{1,2}, Nathanael B. Afolabi³, Aishat B. Usman¹, Aderemi O. Kehinde⁴.

1. Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria.
2. School of Community Health Sciences, University of Nevada, Reno, USA.
3. Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
4. Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Nigeria.

*Corresponding author:

Maureen Odochi Anyanwu- Nigeria Field Epidemiology and Laboratory Training Programme- African Field Epidemiology Network.

E mail: maureenanyanwu23@yahoo.com

Postal Code: 200212

Phone number: +234(0)8058290709

Abstract

Objective

Diabetes mellitus (DM) and Tuberculosis (TB) co morbidity is evolving into an emerging epidemic globally. In Nigeria, a high burden of both diseases respectively exists with limited information on Tuberculosis-Diabetes mellitus (TB-DM) comorbidity. We determined the fasting blood glucose (FBG) level among patients with TB and factors associated with TB-DM comorbidity in Oyo State, South-west Nigeria.

Methods

A cross-sectional study was conducted among TB patients aged 15 years and above, who were selected using a multistage sampling. Data were collected on patients' bio data, anthropometric measurements and FBG levels using a pretested semi-structured questionnaire. The FBG test was conducted on confirmed Pulmonary TB patients (old and newly diagnosed TB patients) at any stage of anti-tuberculosis treatment. Background characteristics and FBG level were summarized using descriptive statistics and factors associated with TB-DM comorbidity were presented using odds ratios (OR) at 95% Confidence Interval.

Results

Of the 404 TB patients, 30 (7.4%) had Impaired Fasting Glucose and 32(7.9%) diagnosed with diabetes. The TB-DM patients' mean age was 49.5 (\pm 15.91) years. There was a female preponderance (10.6%) for TB-DM. Median FBG level for the patients was 88 (Interquartile range: Q1: 99, Q3:79) mg/dl. Being at least 40 years [(OR 3.93; 95% CI: 1.72-8.98)], marital status [(OR= 11.18; 95% CI: 1.68-74.51)] and middle socioeconomic status [(OR=0.4; 95% CI: 0.14-0.98)] were associated with comorbidity individually. The results of the adjusted odds ratio show that only age was marginally associated, $P=0.06$ and [(OR=2.46; 95% CI: 0.97-6.21)].

Conclusion

Tuberculosis-Diabetes mellitus was prevalent among studied population in South-west Nigeria. We recommend the integration of DM screening within the continuum of care for TB management.

Key words: Tuberculosis-Diabetes mellitus comorbidity, Hyperglycaemia, Nigeria.

Article summary:

Strengths and limitations of the study

- This is one of the few studies documenting TB-DM comorbidity in Nigeria.
- It suggests the need for integration of DM screening in the management of TB patients to reduce the burden of these two diseases.
- This study adds to the volume of documented evidence that more studies should be conducted and documented, especially in low-to-middle-Income countries that have and are experiencing an increase in DM prevalence, coupled with a high burden of TB globally.
- Tendency for social desirability bias with reporting lifestyle habits such as alcohol consumption and drug use might have occurred is a limitation of this study.
- The outcomes of TB management in TB-DM comorbid individuals such as cure rate, treatment success rate or death could not be ascertained being a cross-sectional study.

Introduction

Tuberculosis remains a major global infectious disease that causes morbidity and death. The low- and middle-income countries harbor about 95% and 75% of tuberculosis (TB) and

diabetes mellitus (DM) patients respectively.^{1,2} Incident cases of TB were reported to be the highest among people with impaired immunity, human immunodeficiency virus (HIV)

infection, or DM.² In 2018, an estimated 10.0 million individuals were newly diagnosed with TB, 1.2 million and 250,000 people died among HIV-negative and HIV- positive people

respectively, of which Africa region accounted for 24%.³ Nigeria belongs to one of the 30 high-burden TB countries worldwide.³ In 2018, Nigeria was among the top 8 high TB burden countries, with an estimated 429,000 incident TB cases (219 per 100,000 population); and mortality of 123,000 (64 per 100,000 population) those due to excluding TB-HIV.³ Nigeria, with a population of more than 190 million,⁴ has the highest burden of the disease in the with a total TB incidence of 418,000 (219 per 100,000).⁵

Despite the success of the TB control strategies, TB persists in several parts of the world.⁵ This signifies the need to intensify control efforts that identify and address the individual and social determinants of the disease. Structural factors, such as suboptimal case detection and non-adherence to therapy, as well as host-level factors, such as HIV and diabetes mellitus

(DM) that increase vulnerability to active TB are major challenges to TB control.^{6,7}

In 2019, according to International Diabetes Federation (IDF),⁸ there were an estimated 463.0 million and 19.4 million people with DM globally and in Africa respectively. By 2030, it is projected that 28.6 million adults in the Africa region will have DM.⁸ In 2019, an estimated 4.2 million (20-79 years) and more than 366,200 deaths globally and in Africa respectively, could be attributed to DM.⁸ In Nigeria, the prevalence of DM in the general population was 4.3% and 2% of total death in all ages was caused by the disease.⁹

Many studies conducted in different parts of the globe have revealed bidirectional association between TB and DM.¹⁰ This close link is striking in developing countries, where TB is endemic and the burden of DM is high and increasing,¹⁰ including Nigeria.

DM directly impairs innate and adaptive immune responses that are necessary to combat the progression from infection to clinical diseases.¹¹ Diabetes mellitus is a known risk factor for tuberculosis,¹² and is associated with poorer tuberculosis outcomes, while tuberculosis is associated with regressing glycaemic control.¹³ Hence, it is advantageous to screen and identify undiagnosed DM among TB patients and then, offer glycaemic control, to prevent or delay diabetes-related complications and improve TB treatment outcome accordingly.

Despite the evidence which support DM as a risk factor for TB, few studies have been documented in Nigeria. No study has been conducted and reported in Oyo State to the best of our knowledge. This study aimed at determining the prevalence of DM and its associated

factors among patients attending Directly Observed Treatment Centres (DOTS) in Oyo State, South-west, Nigeria.

Methods

Study setting

Oyo State is in South-west Nigeria, the most populous country in sub-Saharan Africa. It has 33 Local Government Areas (LGAs) distributed over its three (3) senatorial districts. The State has 244 Directly Observed Treatment Centre-Short course (DOTS) centres across the 33 LGAs in Oyo State; comprising 200 public and 44 private DOTS centres. All the LGAs have several DOTS centres and are supported by Damien Foundation, Belgium, a leading Non-Governmental Organization (NGO) with focus on effective TB management and control. Overall, there were 1,743 TB patients on treatment in all the DOTS clinics in Oyo State as at the time of the study.

Sputum smear microscopy was the prevailing primary test for the diagnosis of pulmonary tuberculosis (PTB) in Nigeria. Smears may be prepared directly from clinical specimens or from concentrated preparations using Ziehl-Nielsen staining or Fluorescent Auramine staining) to observe acid-fast bacilli. A sputum result is positive if at least one tubercle bacillus (acid-fast/fluorescent) is detected on one or more sputum smears. The glycated haemoglobin test is used to both diagnose DM and assess control in DM.

Study design

A cross-sectional facility-based study was conducted among consenting TB patients aged ≥ 15 years attending DOTS centres in Oyo State. Participants were systematically selected in each DOTS centre and respondents aged 15 were part of the selected lot. However, parents/guardians gave consent for participants who were between the ages of 15 and 17 years old. Pregnant TB patients and extra-pulmonary TB cases were excluded from the study. The fasting blood glucose level was ascertained for confirmed old and newly diagnosed pulmonary TB (PTB) patients both at any stage of anti-tuberculosis treatment.

Sampling technique

A stratified sampling approach was used to select the study participants in the first stage. The LGAs were proportionally allocated to the 3 senatorial zones of the State. 11 of the 33 LGAs in Oyo State, Nigeria was selected for the study, using simple random sampling by balloting in each of the 3 senatorial zones, namely, Oyo central (4 out of 11 LGAs were selected), Oyo north (3 out of 13 LGAs were selected) and Oyo south (4 out of 9 LGAs were selected) of the State. In the second stage, one DOTS centre was selected using simple random sampling in each of the 11 LGAs selected, and 404 patients were systematically selected, proportional to size in each of the 11 DOTS centres selected. (Figure). It is worth mentioning that patients who refused to participate in the study were replaced immediately.

Data collection

The study instrument was adapted from an earlier study. Trained data collectors administered the pre-tested interviewer-administered semi-structured questionnaire to the selected TB

patients to collect information on respondents' socio-demographic characteristics, lifestyle factors, clinical characteristics, and socio-economic status.

Data on past medical history and duration of their treatment on anti-TB drugs were extracted from patients' clinical records.

Anthropometric measures: height, weight and waist circumference using standard procedures. Body Mass index (BMI, kg/m²) were obtained using standard procedures: BMI (kg/m²) was calculated as Weight (kg)/Height (m²). Blood pressure was measured in millimeters of mercury (mm Hg) using a digital BP measurement device.

All participants were tested for DM, irrespective of prior diabetes status. Screening for DM among the respondents was done by Fasting Blood Sugar (FBS) test, using an electronic glucometer and test strips (ACCU-CHEK Active by Roche), in the morning at the respective DOTS centres, in respondents who have fasted for at least 8 hours overnight. The DM status was assessed in line with the WHO recommendation for the diagnostic criteria for diabetes and intermediate hyperglycaemia.⁹ (110mg/dl to 125mg/dl - prediabetic/impaired fasting glucose; (≥126mg/dl - diabetic/fasting plasma glucose).

TB patients who were diagnosed with DM were referred to DM clinics situated in Oyo State of Nigeria for prompt and appropriate management.

Data processing and analysis

The dependent variable is diabetes status (Fasting Blood Glucose level). The independent variables include age, sex, residence, education, marital status, occupation, status of HIV, smoking, BMI, drinking of alcohol, family history of diabetes, habit of physical exercise and socio-economic status. The main outcome variables were proportions of patients with a diagnosis of TB-DM and TB without DM (TB-DM co-infection status). Variables were summarized with descriptive statistics. Bivariate analysis using Pearson's chi-squared test or Fisher's Exact Test appropriately was conducted to determine the relationship between dependent variable and other independent variables. Predictors of the outcome variable (DM) was identified with a multiple binary logistic regression analysis. Covariates selected for the adjusted model was predictive, hence all significant variables at 10% level of significance were carried over to the adjusted model. The SES definitions was computed through principal component analysis which aggregates possession of economic household items and divides it into quintiles. In this case, the SES was categorized in 3 quintiles. Results were presented at 5% alpha significant level. Analysis was performed using Epi info version 7 and SPSS Statistical Software.

Ethical consideration

Ethical clearance was obtained from the Ethics Committee of the Oyo State Ministry of Health (reference number: AD 13/479/277, date: 15 November 2016). Informed consent was obtained from the study participants and guardians- for participants below the age of 18 years. Confidentiality of information obtained was maintained. Data were de-identified.

Patient and Public Involvement

Patients and public were not involved in the design of this study. However, patients served as study participants and were recruited after obtaining an informed consent.

Results

The overall prevalence of TB-DM co morbidity was 7.9% (32/404) [95% CI: 5.7- 10.9]. The proportion of IFG TB patients was 7.4% (30/404). The mean age of the male and female respondents were 41 (\pm 14.2) and 36.8 (\pm 15.0) respectively. There was a female preponderance for TB-DM co- morbidity (Table 1). The median FBG level of male and female patients with TB-DM co-morbidity was 89 (Interquartile range:148) and 88 (Interquartile range:319) respectively (Table 2). TB-DM co-morbidity among poor (10.1%) and average (6.1%) socio-economic status (SES) was lower and 9 (22%) had no formal education, and 9 (22%) had no formal education (Table 1).

There was statistically significant association (OR=134.46, CI:40.02-451.73) between respondents who have been previously diagnosed with DM compared to newly diagnosed respondents (Table 2). Other associated factors of TB such as smoking (OR=1.11, CI: 0.49 - 2.48), alcohol intake (OR=0.83, CI: 0.37 - 1.85), close contact with TB patients (OR=0.42, CI:0.09 - 1.81), family history of DM (OR=14.40, CI: 0.75-204.24), duration of TB treatment (OR=0.79, CI: 0.32 - 1.98), intake of other stimulants (OR=0.86, CI:0.25 - 2.95), habit of exercise (OR: 0.61, CI:0.21 - 1.78) and BMI (OR=2.29, CI:0.99 - 5.28) did not show any statistical association with the prevalence of DM among TB patients (Table 2). Respondents 40 years and above were found to be 0.43 times (1/2.33) less likely to have TB-DM comorbidity compared to those <40 years. Married respondents were 0.43 times (1/2.32) less likely to have TB with DM co-morbidity than unmarried ones. Respondents who were not living with a spouse were 0.26 times (1/3.79) less likely to have TB-DM comorbidity than respondents who were single (Table 3).

Table 1: Socio-demographic characteristics of diabetic and non-diabetic Tuberculosis patients

	Diabetics n (%)	Non- diabetics n (%)	Total n (%)	P-value
Sex				
Male	16(6.3)	237(93.7)	253(62.6%)	0.124
Female	16(10.6)	135(89.4)	151(37.4%)	
Age				
15-24	1(1.7)	57(98.3)	58(14.4)	0.000
25-44	11(5.1)	203(94.9)	214(53.0)	
45-64	12(12.2)	86(87.8)	98(24.3)	
≥65	8(23.5)	26(76.5)	34(8.4)	
Religion				
Christian	9(8.3)	99(91.7)	108(26.7)	0.853
Muslim	23(7.8)	273(92.2)	296(73.3)	
Educational level				
No formal Education	9(22.0)	32(78.0)	41(10.1)	0.02
Primary school	11(9.7)	102(90.3)	113(28.0)	
Secondary school	10(4.5)	205(95.3)	215(53.2)	
University/ Higher education	2(5.7)	32(94.3)	35(8.7)	
Marital status				
Single	2(2.4)	82(97.6)	84(21.0)	0.025
Married	27(8.8)	279(91.2)	306(75.4)	
Divorced/Separated/Widowed	3(21.4)	11(78.6)	14(3.5)	
Place of residence				
Urban	24(8.2)	269(91.8)	293(72.5)	0.744
Rural	8(7.2)	103(92.8)	111(24.5)	
Occupation				
Govt/Private employed	2(5.9)	32(94.1)	34(8.4)	0.296
Self-employed	25(8.3)	277(91.7)	302(74.8)	
Student	1(2.4)	40(97.6)	41(10.1)	
Unemployed	4(14.8)	23(85.2)	27(6.7)	
Average monthly income (Naira)				
< 18,000	15(6.6)	211(93.4)	226(55.9)	0.202
18,000-50,000	9(7.6)	109(92.4)	118(29.2)	
> 51,000	8(13.3)	52(82.6)	60(14.9)	
Ethnicity				
Yoruba	31(7.7)	360(92.1)	391(96.8)	0.975
Others (Hausa, Ibo, etc)	1(0.2)	12(92.3)	13(3.2)	
Socio Economic Status				
Poor	7(10.1)	62(89.9)	69(17.0)	0.098
Average	19(6.4)	278(93.6)	297(73.5)	
Rich	6(15.8)	32(84.2)	38(9.4)	

Table 2: Factors associated with diabetes status among TB patients

Characteristics	Diabetics n (%)	Total	DM among TB patients OR (95% C.I)
Age group			
<40	8 (3.7)	219	1.00
40+	24 (12.9)	185	3.93(1.72 - 8.98)
Marital Status			
Single	2 (2.4)	84	1.00
Married	27 (8.8)	306	3.97 (0.92-17.04)
Divorced/Separated/Widowed	3 (21.4)	14	11.18 (1.68 -74.51)
Socio Economic Status			
Poor	7 (10.1)	69	0.60 (0.19-1.94)
Average	19 (6.4)	297	0.37 (0.14-0.98)
Rich	6 (15.8)	38	1.00
Educational Level			
No formal education	9 (22.0)	41	4.64 (0.93 -23.16)
Primary school	11(9.7)	113	1.78 (0.38-8.44)
Secondary school	10 (4.7)	215	0.81 (0.17-3.84)
University/higher education	2 (5.7)	35	1.00
Told in the past that you have DM?			
Yes	19(82.6)	23	134.46 (40.02 – 451.73)
No	13(3.4)	381	1.00
Smoking			
Yes	9(8.5)	106	1.11 (0.49 – 2.48)
No	23(7.7)	298	1.00
Drinking Alcohol			
Yes	9(7.0)	128	0.83 (0.37 – 1.85)
No	23(8.3)	276	1.00
Duration of TB treatment			
< 1 month	26(8.3)	314	0.79 (0.32 – 1.98)
> 1 month	6(7.5)	90	1.00
Do you take any other stimulant?			
Yes	3(7.0)	43	0.86 (0.25 – 2.95)
No	29(8.0)	361	1.00
Habit of exercise			
Yes	4(5.3)	75	0.61 (0.21 – 1.78)
No	28(8.5)	329	1.00
BMI (Kg/m²)			
Underweight	8(4.8)	167	1.00
Normal	22(10.3)	213	2.29 (0.99 – 5.28)
Overweight/Obese	2(8.3)	24	1.81 (0.36 – 9.06)
Family History of Diabetes Mellitus			
Yes	1(50.0)	2	12.00 (0.73 – 196.00)
No	31(7.7)	402	1.00
Close contact with TB patient			
Yes	2(3.8)	53	0.42 (0.10 – 1.81)
No	30(8.6)	351	1.00

Table 3: Multivariate analysis of significant predictors of DM

Characteristics	Adjusted Odds Ratio (95% CI)	p-value
Age group		
<40 (ref)	1.00	
40+	2.33 (0.92-5.89)	0.073
Educational level		
No formal education	2.54 (0.43-14.81)	0.300
Primary school	1.13 (0.22-5.87)	0.884
Secondary school	0.65 (0.13-3.32)	0.604
University/higher education (ref)	1.00	
Marital Status		
Single (ref)	1.00	
Married	2.32 (0.47-11.49)	0.301
Divorced/Separated/Widowed	3.79 (0.47-30.36)	0.210
Socio Economic Status		
Poor	0.76 (0.21-2.78)	0.680
Average	0.46 (0.16-1.39)	0.170
Rich (ref)		
BMI (Kg/m²)		
Underweight (ref)	1.00	
Normal	2.82 (1.15-6.94)	0.024
Overweight/Obese	1.67 (0.31-9.03)	0.552

*=statistically significant at $\leq 5\%$

Discussion

Our study revealed that the prevalence of DM among diagnosed TB patients was 7.9%. Factors associated with TB-DM co-morbidity were age (being at least 40 years of age), marital status and poverty. Although, the above-mentioned factors were not shown to be significant risk at the multivariate level. Screening for DM in TB patients could improve DM case detection and early initiation of treatment, education of patients and correction of hyperglycaemia, which potentially could have positive effects on the outcome of TB treatment.

The prevalence of DM in this study is quite alarming, recalling that in Nigeria, the most recent prevalence of DM in the general population was 4.3%. This is similar to 4.6% as reported by Shittu et al in a similar population in the Oke-Ogun geo-political zone of Oyo State, Nigeria.¹⁴

The prevalence of 7.9% in our study is comparable with the studies conducted in Uganda (8.5%),¹⁵ and Ethiopia (8.3%).¹⁶ However, the current findings were lower than what were reported from Taiwan (29.5%),¹⁷ Southern-Mexico (29.3%),¹⁸ Kerala-India (44%),¹⁹ Lagos, Nigeria (12.3%).²⁰ The reported finding in Tanzania was lower (4%).²¹ Reasons for the observed variation in prevalence might be related to differences in background between populations (rural and urban settings) and screening methods (RBS, FBS and Oral Glucose Tolerance Test etc.) used in DM diagnosis.

The prevalence of IFG in this study was 7.4%. This finding is similar to the study done in Taian, Dingxi, Jinan, Shijiazhuang, Guiyang- China (7.8%),²² Gujarat-India (7%),²³ higher than Kolar-India (3.1%),²⁴ but lower than the study findings from Gondar-Ethiopia (29.6%), Addis Ababa-Ethiopia (26.7%) and Tamil Nadu-India (24.5%),²⁵⁻²⁷ respectively. Individuals with Impaired Fasting Glucose are at high risk of progressing to type 2 DM, although this is not inevitable,⁹ and this may go further to indicate an increased risk of DM in the future in Nigeria. The observed DM and IFG prevalence in our study poses threats to gains made in TB control; hence, necessitates integrated health services approach to effectively address the burden of the two diseases.

The TB-DM co-morbidity demonstrated an association with older age. Occurrence of DM in older people is consistent with studies done in Addis Ababa-Ethiopia,²⁶ Ethiopia,²⁸ Kerala-India,¹⁹ Tamil Nadu-India,²⁷ Brazil,²⁹ Southern-Mexico,¹⁸ and China.³⁰ This may be due to the fact that DM is essentially an age-related illness that occur more in people older than 40 years. This is consistent with earlier studies conducted to determine the risk factors for TB.³¹ Old age is related to immunosuppression and is one of the risk factors for both TB and DM.^{8,2} In Nigeria, for example, the risk of developing DM increases 3-4 folds after the age of 44 years,¹⁴ a consistent finding with this study, as age group > 44 years had a higher proportion of TB with DM co-morbidity. This goes to strongly suggest that health care system in Nigeria should improve its content and delivery of services with respect to older age.

1
2
3 A slightly higher preponderance TB-DM co-morbidity among females than males in this
4 study is similar to those found in studies done in Ethiopia,¹⁶ and Mexico.³² The prevalence
5
6 and complication of diabetes are more pronounced in females than males as a result of gender
7 associated adiposity.³³ Unlike for men, increased androgen levels induce insulin resistance in
8 women,³³ and increase the risk of type 2 Diabetes and cardiovascular diseases.³⁴ Women
9
10 have a higher percentage of body fat and more often develop peripheral adiposity, where men
11 accumulate fat centrally.³⁵ Women generally have poorer glycemic control.^{36 37} The health
12 system in Nigeria should be geared towards ensuring that concerned females are duly
13
14 educated on preventive measures against DM and encouraged to utilise availability health
15 services to halt the trend of DM among this female gender in Nigeria.
16
17

18 Positive family history is a known risk factor for DM.³⁸ However, there was no significant
19 association with DM among TB patients who have a family history/genetic pre-disposition to
20 DM. This finding is in contrast with the study done in Tamil Nadu-India and China.^{27 39}
21
22

23 Tuberculosis is a disease of poverty, and that is understandably consistent with the
24 finding in this study, as quite a comparable proportion of the TB patients were poor
25 and average in status as well as rich. This indicates a lack of adequate resources to a large
26 proportion of the participants and therefore, a factor to be considered in the management of
27 the disease. Thus, accessing healthcare is a challenge for people living with diabetes in
28
29

30 Nigeria.

31 Majority of the respondents (78.0%) had no formal education. Many factors are shown to affect
32 the health of individuals and communities, namely, low educational level, which
33
34

35 relates to poor health, higher stress level and lower self-esteem.⁴⁰ Educational programmes that
36 embody and emphasize awareness of DM and its preventative measures and
37
38

39 complications, self-care management behaviour (adherence to diabetic medications, healthy
40 diet, regular exercise and follow up should be effectively propagated across all levels. Death of a
41 spouse currently ranks as the life-event needing the most intense social readjustment and poses
42 health risks.⁴¹
43
44
45

46 **Strengths and limitation**

47
48 This is one of the few studies on TB-DM comorbidity to be conducted and further documented in
49 Nigeria, as at the time of study. The findings are generalizable to similar settings in Nigeria and
50 other low-and-middle- income countries. The outcomes of TB management in TB-DM comorbid
51 individuals such as cure rate, treatment success rate or death could not be ascertained being a
52 cross-sectional study.
53
54
55
56
57
58
59
60

Conclusion

There was a high prevalence of DM among TB patients. Age, educational level and marital status were associated with TB-DM co morbidity in this study. Although, not revealed to be significant risk factors at the multivariate level. Widowhood poses health risks. Hence, we recommend that physicians should also be aware of possible long-term health risks emerging after widowhood such as changes in lifestyle, diet and adiposity, which may be remedied by attention to healthy behaviour.

We hope that data obtained would be used to inform a new holistic national treatment guideline for TB, inclusive of routine screening for DM and an active management of the glycaemia in those found in TB-DM co-morbid individuals. These would result in improved treatment outcome and management in PTB patients.

Acknowledgments

We wish to acknowledge Dr Anthonia Ogbera for sharing the study instrument, adapted for this study, responsible health facility staff of the respective healthcare centres where this study was conducted and the United States-Centres for Disease Control and Prevention for technical support and Nigeria Field Epidemiology and Laboratory Training Programme (NFELTP) for providing financial support.

Authors' contributions

MOA, AK were involved in the conception, design and execution of the study. MOA, AK and NA were involved in the analysis and data interpretation. OA contributed to data interpretation; drafting, formatting and final revision of the manuscript for intellectual content. MOA, OA, and AU reviewed the manuscript for intellectual content. All authors read and agreed to final version of the manuscript.

Data Availability Statement

All relevant data to the study are included in the article or uploaded as supplementary information.

Funding

This work was funded by the United States Centres for Disease Control and Prevention through African Field Epidemiology Network to the Nigeria Field Epidemiology and Laboratory Training Programme (Cooperative Agreement Number: U2GGH001876).

Competing interests

None declared.

References

1. Harries AD, Murray MB, Jeon CY et al. Defining the research agenda to reduce the joint burden of disease from diabetes mellitus and tuberculosis. *Trop Med Int Health*. 2010;15:659-63.
2. Sen T, Shashank R, Zarir F. Tuberculosis and Diabetes Mellitus: Merging Epidemics. *J Assoc. Physicians India* . 2009; 57:62-65.
3. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/global_report/en/, accessed 27th May 2020).
4. National Population Commission (NPC) [Nigeria] 2006 Population and Housing Census of the Federal Republic of Nigeria. Abuja, Nigeria: National Population Commission; 2006.
5. WHO Global tuberculosis report 2018. Geneva: World Health Organization; 2018 (https://www.who.int/tb/publications/global_report/en/, accessed 27th May 2020).
6. Golsha R, Rezaei SR, Shafiee A, et al. Pulmonary tuberculosis and some underlying conditions in Golestan Province of Iran, during 2001–2005. *J. Clin. Diag. Res*. 2009; 3(1), 1302–1306.
7. Lönnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. *Soc. Sci. Med* .2009; 68:2240-2246.
8. International Diabetes Federation. IDF Diabetes Atlas (Internet). 7th edn: 2015. www.diabetesatlas.org (Accessed 6th June 2016).
9. World Health Organization. Global report on diabetes. Diabetes Country profiles (Internet).2016. <https://www.who.int/diabetes/publications/grd-2016/en/> Accessed 6th June, 2016.
10. Baghaei P, Marjani M, Javanmard P et al. Diabetes mellitus and tuberculosis facts and controversies. *J Diabetes Metab Disord*. 2013;12:58.
11. Zhou T, Hu Z, Yang S et al. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. *J Diabetes Res*. 2018; 2018:7457269.
12. Jeon CY, Murray, MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. *PLoS Med*; 2008; 5:152.
13. Riza AL, Pearson F, Ugarte-Gil, C et al. Clinical management of concurrent Diabetes and Tuberculosis and the implications for patient services. *Lancet Diabetes Endocrinology*; 2013; 2:740-753.
14. Shittu RO, Kasali FO, Biliaminu SA et al. Prevalence of Diabetes and Pre-diabetes in Oke-Ogun Region of Oyo State, Nigeria. *J Med Res Health Educ*.2017; 1:1.

15. Kibirige D, Ssekitoleko R, Mutebi E et al. Overt diabetes mellitus among newly diagnosed Ugandan tuberculosis patients: a cross-sectional study. *BMC Infect Dis*. 2013; 13:122.
16. Workneh MH, Bjune GA, Yimer SA. Prevalence and Associated Factors of Diabetes Mellitus among Tuberculosis Patients in South-Eastern Amhara Region, Ethiopia: A Cross Sectional Study. *PLoS One*. 2016;11:1.
17. Chang JT, Dou HY, Yen, CY et al. Effect of type-2 diabetes on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multi drug resistance. *J Formos med Asbc*. 2011;110: 372-381.
18. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L et al. Association of diabetes and tuberculosis: Impact on treatment and post-treatment outcome. *Thorax*. 2013;68: 214-220.
19. Balakrishna S, Vijayan S, Nair S et al. High diabetes prevalence among tuberculosis cases in Kerala, India. *PLoS One*. 2012;7: e46502.
20. Ogbera AO, Kapur A, Chinenye S et al. Undiagnosed Diabetes Mellitus in Tuberculosis: A lagos report. *Indian J Endocrinol metab*. 2014; 18:475-479.
21. Mugusi F, Swai AB, Alberti KG et al. Increased prevalence of Diabetes Mellitus in patients with Pulmonary Tuberculosis in Tanzania. *Tubercle*. 1990; 71: 271-276.
22. Li L, Lin Y, Mi F et al. Screening of patients with tuberculosis for Diabetes Mellitus in China. *Trop Med Int Health*. 2012;17: 1294-301.
23. Dave P, Shah A, Chauhan M et al. Screening patients with tuberculosis for Diabetes Mellitus in Gujarat, India. 2013; 3 (Suppl 1): S29–S33.
24. Naik B, Kumar A MV, Satyanarayana S et al. Is screening for diabetes among tuberculosis patients feasible at the field level? *Public Health Action*. 2013;3 (Suppl 1):S34-S37.
25. Getachew A, Mekonnen S, Alemu S et al. High magnitude of Diabetes Mellitus among Active Pulmonary Tuberculosis Patients in Ethiopia. *British Journal of Medicine & Medical Research*. 2014;4:862-872.
26. Damtew E, Ali I, Meressa D. Prevalence of Diabetes Mellitus among Active Pulmonary Tuberculosis patients at St Peter specialized Hospital, Addis Ababa, Ethiopia. *World Journal of medical Sciences*. 2014;1:389-396.
27. Viswanathan V, Kumpatla S, Aravindalochann V et al. Prevalence of Diabetes and Pre-diabetes mellitus and associated risk factors among tuberculosis patients in India. *PLoS One*. 2012;7:e41367.
28. Amare H, Gelaw A, Anagaw B, Gelaw B. Smear positive pulmonary tuberculosis among diabetic patients at the Dessie referral hospital, Northeast Ethiopia. *Infect Dis Poverty*. 2013;2:6.
29. Reis SB, Gomes T, Locatelli R et al. Treatment outcomes in Tuberculosis patients with diabetes: A polytomous analysis using Brazilian surveillance system. *PLoS One*. 2014;9:7: e100082.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
30. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly Detected Pulmonary Tuberculosis Patients in China: A Community Based Cohort Study. *PLoS One*. 2013. 8(12): e82660.
31. Lienhardt C, Fielding K., Sillah JS et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. *Int J Epidemiol* 2005; 34: 914-923.
32. Delgado-Sánchez G, García-García L, Castellanos-Joya M et al. Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000-2012. *PLoS One*.2015;10:e0129312.
33. Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. *Physiol Behav*. 2018;187:20-23.
34. Ding EL, Song Y, Malik, VS et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2006;295:1288-1299.
35. Blaak E. Gender differences in fat metabolism. *Curr Opin Clin Nutr Metab Care*. 2001;4:499-502.
36. Sharev V, Chodick G, Heyman AD et al. Gender differences in healthcare utilization and medical indicators among patients with diabetes. *Public health*. 2005;119:45-49.
37. Chiu CJ, Wray LA. Gender differences in functional limitations in adults living with type 2 diabetes: bio behavioural and psychosocial mediators. *Ann Behav Med* .2011; 41:71-82.
38. International Diabetes Federation Atlas, 6th Edition. International Diabetes Federation, 2013. <http://www.idf.org/diabetesatlas>.
39. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly Detected Pulmonary Tuberculosis Patients in China: A Community Based Cohort Study. *PLoS One*. 2013; 8: e82660.
40. World Health Organization. 2012. The determinants of health. Health Impact Assessment. <https://www.who.int/hia/evidence/doh/en> .Accessed 5 June 2016.
41. Strobe M, Schut H, Strobe W. Health outcomes of bereavement. *Lancet*. 2007;370: 1960-1973.

1
2
3 **Figure:** Sampling strategy flow chart
4

5
6 Oyo central senatorial zone: Akinyele, Egbeda, Ona-ara, Oyo East
7

8 Oyo north senatorial zone: Saki west, Kajola, Iseyin

9 Oyo south senatorial zones: Ibadan North East, Ibadan North West, Ibadan South East, Ibadan
10 South West.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure
Sampling strategy flow chart

210x297mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
	(c) Explain how missing data were addressed	Not Applicable (N/A)	
	(d) If applicable, describe analytical methods taking account of sampling strategy	6	
	(e) Describe any sensitivity analyses	N/A	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	(uploaded)
Descriptive data	14*	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-11

1			
2	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included
3			
4			
5			
6			(b) Report category boundaries when continuous variables were categorized
7			
8			
9			
10			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
11			
12			
13	Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses
14			
15			
16	Discussion		
17	Key results	18	Summarise key results with reference to study objectives
18			
19			
20	Limitations	19	Discuss limitations of the study, considering sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
21			
22			
23			
24	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
25			
26			
27	Generalisability	21	Discuss the generalisability (external validity) of the study results
28			
29			
30	Other information		
31	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
32			
33			
34			
35			

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Diabetes Mellitus and Its Associated Factors among Tuberculosis Patients Attending Directly Observed Treatment Centres in Oyo State, Nigeria: A cross sectional evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059260.R1
Article Type:	Original research
Date Submitted by the Author:	10-Feb-2022
Complete List of Authors:	Anyanwu, Maureen; African Field Epidemiology Network Nigeria Ajumobi, Olufemi; University of Nevada Reno School of Community Health Sciences Afolabi, Nathanael; University of Ibadan, Department of Epidemiology and Medical Statistics Usman, Aishat; African Field Epidemiology Network Nigeria Kehinde, Aderemi; College of Medicine, University of Ibadan, Department of Medical Microbiology and Parasitology
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Tuberculosis < INFECTIOUS DISEASES, PUBLIC HEALTH, Epidemiology < TROPICAL MEDICINE, Tropical medicine < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Diabetes Mellitus and Its Associated Factors among Tuberculosis**
5 2 **Patients Attending Directly Observed Treatment Centres in Oyo**
6 3 **State, Nigeria: A cross sectional evaluation**
7
8

9 4 Maureen O. Anyanwu^{1*}, Olufemi O. Ajumobi², Nathanael B. Afolabi³, Aishat B. Usman¹,
10 5 Aderemi O. Kehinde⁴.

- 11
12
13 6 1. African Field Epidemiology Network, Nigeria.
14 7 2. University of Nevada, Reno School of Community Health Sciences, Nevada, USA.
15 8 3. Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of
16 9 Medicine, University of Ibadan, Nigeria.
17 10 4. Department of Medical Microbiology and Parasitology, Faculty of Basic Medical
18 11 Sciences, College of Medicine, University of Ibadan, Nigeria.
19
20
21
22

23 13 *Corresponding author:

24
25 14 Maureen Odochi Anyanwu- Nigeria Field Epidemiology and Laboratory Training
26 15 Programme- African Field Epidemiology Network Nigeria.

27
28
29 16 E mail: maureenanyanwu23@yahoo.com

30
31 17 Postal Code: 900108

32
33 18 Phone number: +234(0)8058290709
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Objective**

3 Diabetes mellitus (DM) and Tuberculosis (TB) co-morbidity is evolving into an emerging
4 epidemic globally. In Nigeria, a high burden of both diseases respectively exists with limited
5 information on Tuberculosis-Diabetes Mellitus (TB-DM) comorbidity. We determined the
6 fasting blood glucose (FBG) level among patients with TB and factors associated with TB-
7 DM comorbidity in Oyo State, South-west Nigeria.

8 **Methods**

9 A cross-sectional study was conducted among TB patients aged 15 years and above, who
10 were selected using multistage sampling. Data were collected on patients' biodata,
11 anthropometric measurements and FBG levels using a pretested semi-structured
12 questionnaire. The FBG test was conducted on confirmed Pulmonary TB patients (old and
13 newly diagnosed TB patients) at any stage of anti-tuberculosis treatment. Background
14 characteristics and FBG level were summarized using descriptive statistics and factors
15 associated with TB-DM comorbidity were presented using odds ratios (OR) at 95%
16 Confidence Interval.

17 **Results**

18 Of the 404 TB patients, 30 (7.4%) had Impaired Fasting Glucose and 32 (7.9%) were
19 diagnosed with diabetes. The TB-DM patients' mean age was 49.5 (SD:15.9) years. Females
20 were more likely than males to have diabetes (10.6% vs. 6.3%). Median FBG level for the
21 patients was 88 (Interquartile range: Q1: 99, Q3:79) mg/dl. Being at least 40 years [(OR 3.93;
22 95% CI: 1.72-8.98)], marital status [(OR= 11.18; 95% CI: 1.68-74.51)] and middle
23 socioeconomic status [(OR=0.4; 95% CI: 0.14-0.98)] were associated with comorbidity
24 individually. In the multivariable model, only body mass index was independently and
25 significantly associated with diabetes.

26 **Conclusion**

27 Tuberculosis-Diabetes Mellitus was prevalent among the studied population in South-west
28 Nigeria. We recommend the integration of DM screening within the continuum of care for
29 TB management.

30
31 **Keywords:** Tuberculosis-Diabetes Mellitus comorbidity, Hyperglycaemia, Nigeria.

Article summary:**• Strengths and limitations of the study**

- This is one of the few studies to document TB-DM comorbidity in Nigeria and the first to do so for Oyo State, South-west, Nigeria.
- The high prevalence of DM among TB patients in Oyo State is a new and important finding for addressing the dual non-communicable and communicable disease burden.
- Our study used a hospital design that enabled access to TB patients in a clinic setting and this approach is a potential opportunity for implementing concurrent regular routine screening and clinical management, lifestyle modification, and follow-up for TB-DM comorbidity.
- Alcohol consumption and smoking are culturally undesirable behaviour, and these could have resulted in socially desirable responses.
- The outcomes of TB management in TB-DM comorbid individuals such as cure rate, treatment success rate, or death could not be ascertained in our study, which was a cross-sectional evaluation.

1 Introduction

2 Tuberculosis remains a major global infectious disease that causes morbidity and death. The
3 low- and middle-income countries harbor about 95% and 75% of tuberculosis (TB) and
4 diabetes mellitus (DM) patients respectively.^{1,2} Incident cases of TB were reported to be the
5 highest among people with impaired immunity, human immunodeficiency virus (HIV)
6 infection or DM.² In 2018, an estimated 10.0 million individuals were newly diagnosed with
7 TB, 1.2 million and 250,000 people died among HIV-negative and HIV- positive people
8 respectively, of which Africa region accounted for 24%.³ Nigeria belongs to one of the 30
9 high-burden TB countries worldwide.³ In 2018, Nigeria was among the top 8 high TB burden
10 countries, with an estimated 429,000 incident TB cases (219 per 100,000 population); and
11 mortality of 123,000 (64 per 100,000 population) those due to excluding TB-HIV.³ Nigeria,
12 with a population of more than 190 million,⁴ has the highest burden of the disease
13 globally with a total TB incidence of 418,000 (219 per 100,000).⁵

14 Despite the success of the TB control strategies, TB persists in several parts of the world.⁵
15 This signifies the need to intensify control efforts that identify and address the individual and
16 social determinants of the disease. Structural factors, such as suboptimal case detection and
17 non-adherence to therapy, as well as host-level factors, such as HIV and diabetes mellitus
18 (DM), that increase vulnerability to active TB are major challenges to TB control.^{6,7}

19 In 2019, according to International Diabetes Federation (IDF),⁸ there were an estimated 463.0
20 million and 19.4 million people with DM globally and in Africa respectively. By 2030, it is
21 projected that 28.6 million adults in the Africa region will have DM.⁸ In 2019, an estimated
22 4.2 million (20-79 years) and more than 366,200 deaths globally and in Africa respectively,
23 could be attributed to DM.⁸ In Nigeria, the prevalence of DM in the general population was
24 4.3% and 2% of total death in all ages was caused by the disease.⁹

25 Many studies conducted in different parts of the globe have revealed a bidirectional
26 association between TB and DM.¹⁰ This close link is striking in developing countries, where
27 TB is endemic and the burden of DM is high and increasing,¹⁰ including Nigeria.

28 DM directly impairs innate and adaptive immune responses that are necessary to combat the
29 progression from infection to clinical diseases.¹¹ Diabetes mellitus is a known risk factor for
30 tuberculosis,¹² and is associated with poorer tuberculosis outcomes, while tuberculosis is
31 associated with regressing glycaemic control.¹³ Hence, it is advantageous to screen and
32 identify undiagnosed DM among TB patients and then, offer glycaemic control, in order to
33 prevent or delay diabetes-related complications and improve TB treatment outcomes
34 accordingly.

35 Despite the evidence which supports DM as a risk factor for TB, few studies have been
36 documented in Nigeria. No study has been conducted and reported in Oyo State to the best of
37 our knowledge. This study aimed at determining the prevalence of DM and its associated
38 factors among patients attending Directly Observed Treatment Centres (DOTS) in Oyo State,
39 South-west, Nigeria.

40

1 **Methods**

2 **Study setting**

3 Oyo State is in South-west Nigeria, the most populous country in sub-Saharan Africa. It has
4 33 Local Government Areas (LGAs) distributed over its three (3) senatorial districts. The
5 State has 244 Directly Observed Treatment Centre-Short course (DOTS) centres across the
6 33 LGAs in Oyo State, comprising 200 public and 44 private DOTS centres. All the LGAs
7 have several DOTS centres and are supported by Damien Foundation, Belgium, a leading
8 Non-Governmental Organization (NGO) with a focus on effective TB management and
9 control. Overall, there were 1,743 TB patients on treatment in all the DOTS clinics in Oyo
10 State at the time of the study.

11 Sputum smear microscopy was the prevailing primary test for the diagnosis of pulmonary
12 tuberculosis (PTB) in Nigeria. Smears may be prepared directly from clinical specimens or
13 from concentrated preparations using Ziehl-Nielsen staining or Fluorescent Auramine
14 staining) to observe acid-fast bacilli. A sputum result is positive if at least one tubercle
15 bacillus (acid-fast/fluorescent) is detected on one or more sputum smears. The glycated
16 haemoglobin test is used to both diagnose DM and assess control in DM.

17 **Study design**

18 A cross-sectional facility-based study was conducted among consenting TB patients aged
19 15years and above attending DOTS centres in Oyo State. Participants were systematically
20 selected in each DOTS centre. There was no age-cut off for the study and no participant
21 under the age of 15 years was selected. However, parents/guardians gave consent for
22 participants who were between the ages of 15 and 17 years old. Pregnant TB patients and
23 extra-pulmonary TB cases were excluded from the study. The fasting blood glucose level was
24 ascertained for confirmed old and newly diagnosed pulmonary TB (PTB) patients both at any
25 stage of anti-tuberculosis treatment.

26 **Sampling technique**

27 A stratified sampling approach was used to select the study participants in the first stage. The
28 LGAs were proportionally allocated to the 3 senatorial zones of the State. Eleven (11) of the
29 33 LGAs in Oyo State, Nigeria was selected for the study, using simple random sampling by
30 balloting in each of the 3 senatorial zones, namely, Oyo central (4 out of 11 LGAs were
31 selected), Oyo north (3 out of 13 LGAs were selected) and Oyo south (4 out of 9 LGAs were
32 selected) of the State. In the second stage, one DOTS centre was selected using simple
33 random sampling in each of the 11 LGAs selected, and 404 patients were systematically
34 selected, proportional to the size in each of the 11 DOTS centres selected. (Figure).

35 The minimum sample size of sample 364 was calculated with the formula for estimating a
36 single population proportion ($n = Z^2 p(1 - p)/d^2$), 12.3% proportion,¹⁴ for 0.05 precision and
37 Z of 1.96. The final sample size was 404 TB patients after correcting for a finite population
38 and accounting for a 10% non-response rate.

39

1 **Data collection**

2 The study instrument was adapted from an earlier study. Trained data collectors administered
3 the pre-tested interviewer-administered semi-structured questionnaire to the selected TB
4 patients to collect information on respondents' socio-demographic characteristics, lifestyle
5 factors, clinical characteristics, and socio-economic status.

6 Data on past medical history and duration of their treatment on anti-TB drugs were extracted
7 from patients' clinical records.

8 Anthropometric measures: height, weight and waist circumference using standard procedures.
9 Body Mass Index (BMI, kg/m²) were obtained using standard procedures: BMI (kg/m²) was
10 calculated as Weight (kg)/Height (m²). Blood pressure was measured in millimeters of
11 mercury (mm Hg) using a digital BP measurement device.

12 All participants were tested for DM, irrespective of prior diabetes status. Screening for DM
13 among the respondents was done by Fasting Blood Sugar (FBS) test, using an electronic
14 glucometer and test strips (ACCU-CHEK Active by Roche), in the morning at the respective
15 DOTS centres, in respondents who have fasted for at least 8 hours overnight. The DM status
16 was assessed in line with the WHO recommendation for the diagnostic criteria for diabetes
17 and intermediate hyperglycaemia.⁹ (110mg/dl to 125mg/dl – prediabetic/impaired fasting
18 glucose; (≥126mg/dl – diabetic/fasting plasma glucose).

19 TB patients who were diagnosed with DM were referred to DM clinics situated in Oyo State,
20 Nigeria for prompt and appropriate management.

21 **Data processing and analysis**

22 The dependent variable is diabetes status (Fasting Blood Glucose level). The independent
23 variables include age, sex, residence, education, marital status, occupation, HIV status,
24 smoking, BMI, drinking of alcohol, family history of diabetes, physical activity (exercise)
25 and socio-economic status. The main outcome variables were proportions of patients with a
26 diagnosis of TB-DM and TB without DM (TB-DM co-infection status), and patients with
27 Impaired Fasting Glucose were not included in the non-diabetic group for the analysis.
28 Variables were summarized with descriptive statistics. Bivariate analysis using Pearson's chi-
29 squared test or Fisher's Exact Test appropriately was conducted to determine the relationship
30 between the dependent variable and other independent variables. Predictors of the outcome
31 variable (DM) was identified with a multiple binary logistic regression analysis. Covariates
32 selected for the adjusted model was predictive, hence all significant variables at 10% level of
33 significance were carried over to the adjusted model. The SES definitions were computed
34 through principal component analysis which aggregates possession of economic household
35 items and divides it into quintiles. Each respondent was given a score based on the number
36 and kinds of consumer goods owned or services enjoyed, ranging from radio, television,
37 mobile telephone, refrigerator, cable TV, generating set, air conditioner, computer, electric
38 iron, fan, motorcycle, car/truck, land ownership, house ownership, livestock/other farm
39 animals/poultry and availability of electricity. These scores were derived through principal
40 component analysis and using the first factor that has the highest proportion of information

1 explained (25%) to rank each participant by their score. The score was then divided into three
 2 equal categories, each comprising 33% of the population. In this case, the SES was
 3 categorized into three quintiles. Results were presented at the 5% alpha significant level.
 4 Analysis was performed using Epi info version 7 and SPSS Statistical Software.

	Diabetics n (%)	Non-diabetics n (%)	Total n (%)	P-value
Sex				
Male	16(6.3)	237(93.7)	253(62.6)	0.124
Female	16(10.6)	135(89.4)	151(37.4)	
Age				
15-24	1(1.7)	57(98.3)	58(14.4)	0.000
25-44	11(5.1)	203(94.9)	214(53.0)	
45-64	12(12.2)	86(87.8)	98(24.3)	

5 **Ethical consideration**

6 Ethical clearance was obtained from the Ethics Committee of the Oyo State Ministry of
 7 Health (reference number: AD 13/479/277, date: 15 November 2016). Informed consent was
 8 obtained from the study participants and guardians- for participants below the age of 18
 9 years. Confidentiality of information obtained was maintained. Data were de-identified.

10 **Patient and Public Involvement**

11 Patients and the public were not involved in the design of this study. However, patients
 12 served as study participants and were recruited after obtaining informed consent.

13 **Results**

14 We approached a total of 426 selected patients, replaced immediately those who refused to
 15 participate in the study (n =22) until we attained our sample size of 404 (response rate
 16 =94.8% (404/426). The overall prevalence of TB-DM co-morbidity was 7.9% (32/404) [95%
 17 CI: 5.7- 10.9]. The proportion of IFG TB patients was 7.4% (30/404). The mean age of the
 18 male and female respondents was 41 (\pm 14.2) and 36.8 (\pm 15.0) respectively. There was a
 19 female preponderance for TB-DM co-morbidity (Table 1). The median FBG level of male
 20 and female patients with TB-DM co-morbidity was 89 (Interquartile range:148) and 88
 21 (Interquartile range:319) respectively (Table 2). TB-DM co-morbidity among poor (10.1%)
 22 and average (6.1%) socio-economic status (SES) were lower and 9 (22%) had no formal
 23 education, and 9 (22%) had no formal education (Table 1).

24 Age (aOR: 2.28, 95%CI: 0.91, 5.74) and marital relationships ([being married, aOR: 2.23
 25 95%CI: 0.45 – 10.97] and being separated/divorced/widowed, aOR: 3.80, 95%CI: 0.48 – 30.13])
 26 were not significant predictors of being diabetic TB patient. In the multivariate model, only
 27 body mass index was independently and significantly associated with diabetes (Table 3).

Characteristics	Diabetics n (%)	Total n (%)	OR (95% C.I)
≥65	8(23.5)	26(76.5)	34(8.4)
Religion			
Christian	9(8.3)	99(91.7)	108(26.7) 0.853
Muslim	23(7.8)	273(92.2)	296(73.3)
Educational level			
No formal Education	9(22.0)	32(78.0)	41(10.1)
Primary school	11(9.7)	102(90.3)	113(28.0) 0.02
Secondary school	10(4.5)	205(95.3)	215(53.2)
University/ Higher education	2(5.7)	32(94.3)	35(8.7)
DM Told in the past that you have			
Yes	19(82.6)	23	134.46 (40.02 – 451.73)
No	13(3.4)	82(97.6)	84(21.0) 1.00
Married			
Married	27(8.8)	279(91.2)	306(75.4) 0.025
Divorced/Separated/Widowed	3(21.4)	11(78.6)	14(3.5) 1.11 (0.49 – 2.48)
Smoking			
Yes	9(8.5)	106	
No	23(7.7)	298	1.00
Place of residence			
Urban	24(8.2)	269(91.8)	293(72.5) 0.744
Rural	8(7.2)	103(92.8)	111(24.5)
Occupation			
Govt/Private employed	2(5.9)	32(94.1)	34(8.4)
Self-employed	25(8.3)	277(91.7)	302(74.8) 0.296
Student	1(2.4)	40(97.6)	41(10.1)
Unemployed	4(14.8)	23(85.2)	27(6.7)
Average monthly income (Naira)			
< 18,000	15(6.6)	211(93.4)	226(55.9)
18,000-50,000	9(7.6)	109(92.4)	118(29.2) 0.202
> 51,000	8(13.3)	52(86.7)	60(14.9)
Ethnicity			
Yoruba	31(7.7)	360(92.1)	391(96.8) 0.975
Others (Hausa, Ibo, etc)	1(0.2)	12(92.3)	13(3.2)
Socioeconomic status			
Poor	14(10.5)	120(89.6)	134(33.2)
Average	10(7.4)	126(92.7)	136(33.7) 0.381
Rich	8(6.0)	126(94.0)	134(33.2)

Table 1: Socio-demographic characteristics of diabetic and non-diabetic Tuberculosis patients (n=404)

Drinking Alcohol			
Yes	9(7.0)	128	0.83 (0.37 – 1.85)
No	23(8.3)	276	1.00
Duration of TB treatment			
< 1 month	26(8.3)	314	0.79 (0.32 – 1.98)
> 1 month	6(7.5)	90	1.00
Do you take any other stimulant?			
Yes	3(7.0)	43	0.86 (0.25 – 2.95)
No	29(8.0)	361	1.00
Habit of exercise			
Yes	4(5.3)	75	0.61 (0.21 – 1.78)
No	28(8.5)	329	1.00
BMI (Kg/m²)			
Underweight	8(4.8)	167	1.00
Normal	22(10.3)	213	2.29 (0.99 – 5.28)
Overweight/Obese	2(8.3)	24	1.81 (0.36 – 9.06)
Family History of Diabetes Mellitus			
Yes	1(50.0)	2	12.00 (0.73 – 196.00)
No	31(7.7)	402	1.00
Close contact with TB patient			
Yes	2(3.8)	53	0.42 (0.10 – 1.81)
No	30(8.6)	351	1.00

Table 2: Factors associated with diabetes status among TB patients

Table 3: Multivariable analysis of the predictors of DM

*=statistically significant at $\leq 5\%$

1
2
3 1
4
5
6 2
7
8 3
9

Characteristics	Adjusted Odds Ratio (95% CI)	p-value
Age group		
<40 (ref)	1.00	
40+	2.28 (0.91, 5.74)	0.080
Educational level		
No formal education	2.72 (0.49 – 15.08)	0.252
Primary school	1.06 (0.21 - 5.41)	0.945
Secondary school	0.60 (0.12 - 3.00)	0.532
University/higher education (ref)	1.00	
Marital Status		
Single (ref)	1.00	
Married	2.23 (0.45 – 10.97)	0.323
Divorced/Separated/Widowed	3.80 (0.48 – 30.13)	0.206
BMI (Kg/m²)		
Underweight (ref)	1.00	
Normal	2.91 (1.18-7.14)	0.020
Overweight/Obese	1.75 (0.33 – 9.39)	0.514

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 4
33
34
35 5
36
37
38 6
39
40 7
41
42
43 8
44
45 9
46
47
48 10
49
50 11
51
52

Discussion

Our study revealed that the prevalence of DM among diagnosed TB patients was 7.9%. Factors associated with TB-DM co-morbidity were age (being at least 40 years of age), marital status and poverty. Although, the above-mentioned factors were not shown to be of significant risk at the multivariate level. Screening for DM in TB patients could improve DM

1 case detection and early initiation of treatment, education of patients and correction of
2 hyperglycaemia, which potentially could have positive effects on the outcome of TB
3 treatment.

4 In Nigeria, the most recent prevalence of DM in the general population was 4.3%.⁹ This is
5 similar to 4.6% as reported by Shittu et al in a similar population in the Oke-Ogun geo-
6 political zone of Oyo State, Nigeria.¹⁵ The prevalence of DM in this study is quite alarming
7 (7.9%), it is comparable to the studies conducted in Uganda (8.5%),¹⁶ and Ethiopia (8.3%).¹⁷
8 However, the current findings were lower than what was reported from Taiwan (29.5%),¹⁸
9 Southern-Mexico (29.3%),¹⁹ Kerala-India (44%),²⁰ Lagos, Nigeria (12.3%).¹⁴ The reported
10 finding in Tanzania was lower (4%).²¹ Reasons for the observed variation in prevalence
11 might be related to differences in background between populations (rural and urban settings)
12 and screening methods (RBS, FBS and Oral Glucose Tolerance Test etc.) used in DM
13 diagnosis.

14 The prevalence of IFG in this study was 7.4%. This finding is similar to the study done in
15 Taian, Dingxi, Jinan, Shijiazhuang, Guiyang- China (7.8%),²² Gujarat-India (7%),²³ higher
16 than Kolar-India (3.1%),²⁴ but lower than the study findings from Gondar-Ethiopia (29.6%),
17 Addis Ababa-Ethiopia (26.7%) and Tamil Nadu-India (24.5%),²⁵⁻²⁷ respectively. Individuals
18 with Impaired Fasting Glucose are at high risk of progressing to type 2 DM, although this is
19 not inevitable,⁹ and this may go further to indicate an increased risk of DM in the future in
20 Nigeria. The observed DM and IFG prevalence in our study pose threats to gains made in TB
21 control; hence, necessitates integrated health services approach to effectively address the
22 burden of the two diseases.

23 The TB-DM co-morbidity demonstrated an association with older age. The occurrence of
24 DM in older people is consistent with studies done in Addis Ababa-Ethiopia,²⁶ Ethiopia,²⁸
25 Kerala-India,²⁰ Tamil Nadu-India,²⁷ Brazil,²⁹ Southern-Mexico,¹⁹ and China.³⁰ This may be
26 because DM is an age-related illness that occurs in persons above 40years. This is consistent
27 with earlier studies which determined the risk factors for TB.³¹ Old age is related to
28 immunosuppression and is one of the risk factors for both TB and DM.^{8,2} In Nigeria, for
29 example, the risk of developing DM increases three to four folds after the age of 44 years,¹⁵ a
30 consistent finding with this study where age group > 44 years had a higher proportion of TB
31 with DM co-morbidity. This goes to strongly suggest that the health care system in Nigeria
32 should improve its content and delivery of services with respect to older age groups.

33 A slightly higher preponderance of TB-DM co-morbidity among females than males in this
34 study is similar to those found in studies done in Ethiopia,¹⁷ and Mexico.³² The prevalence
35 and complication of diabetes are more pronounced in females than males as a result of
36 gender-associated adiposity.³³ Unlike for men, increased androgen levels induce insulin
37 resistance in women,³³ and increase the risk of type 2 diabetes and cardiovascular diseases.³⁴
38 Women have a higher percentage of body fat and more often develop peripheral adiposity,
39 whereas men accumulate fat centrally.³⁵ Women generally have poorer glycemic control.^{36,37}
40 The health system in Nigeria should be geared towards ensuring that concerned females are

1
2
3 1 duly educated on preventive measures against DM and encouraged to utilise available health
4 2 services to halt the trend of DM among this female gender in Nigeria.

6 3 Positive family history is a known risk factor for DM.³⁸ However, there was no significant
7 4 association with DM among TB patients who have a family history/genetic predisposition to
8 5 DM. This finding is in contrast with the study done in Tamil Nadu-India and China.^{27 39}

11 6 Tuberculosis is a disease of poverty. In our study, two-thirds of the respondents were of low
12 7 and average socioeconomic status. This portends a lack of adequate resources to a large
13 8 proportion of the participants and could be a challenge for persons living with diabetes in
14 9 Nigeria. Therefore, these should be considered in the management of the disease which
15 10 comes at a huge personal out-of-pocket cost.

19 11 Most of the respondents (78.0%) had no formal education. Many factors are shown to affect
20 12 the health of individuals and communities, namely, low educational level, which relates to
21 13 poor health, higher stress level and lower self-esteem.⁴⁰ Educational programmes that
22 14 embody and emphasize awareness of DM and its preventative measures and complications,
23 15 self-care management behaviour (adherence to diabetic medications, healthy diet, regular
24 16 exercise and follow up should be effectively propagated across all levels. The death of a
25 17 spouse currently ranks as the life-event needing the most intense social readjustment and
26 18 poses health risks.⁴¹

30 19 **Strengths and limitation**

32 20 This is one of the few studies on TB-DM comorbidity conducted and documented in Nigeria,
33 21 at the time of the study. The findings are generalizable to similar settings in Nigeria and other
34 22 low-and-middle-income countries. Alcohol consumption and smoking are culturally
35 23 undesirable behaviour, and these could have resulted in socially desirable responses. The
36 24 outcomes of TB management in TB-DM comorbid individuals such as cure rate, treatment
37 25 success rate or death could not be ascertained in our study being a cross-sectional evaluation.

41 26 **Conclusion**

43 27 There was a high prevalence of DM among TB patients. Age, educational level, and marital
44 28 status were associated with TB-DM co-morbidity in this study. Although not revealed to be
45 29 significant risk factors at the multivariate level, a current single relationship from a previous
46 30 married relationship, that is, being divorced, separated, or widowed, could pose potential
47 31 health risks. Those in a married spousal relationship tends to benefit from social support
48 32 towards adhering to healthy behavioural lifestyle. Hence, we recommend that physicians
49 33 should also be aware of possible long-term health risks emerging after widowhood such as
50 34 changes in lifestyle, diet, and adiposity, which may be remedied by attention to healthy
51 35 behaviour.

56 36 We hope that data obtained would be used to inform a new holistic national treatment
57 37 guideline for TB, inclusive of routine screening for DM and active management of the
58 38 glycaemia in those found in TB-DM co-morbid individuals. These would result in improved
59 39 treatment outcomes and management in PTB patients.

1 Patient and Public Involvement

2 Patients and public were not involved in the design of this study. However, patients served as
3 study participants and were recruited after obtaining an informed consent.

4 Acknowledgements

5 We wish to acknowledge Dr Anthonia Ogbera for sharing the study instrument, adapted for
6 this study, responsible health facility staff of the respective healthcare centres where this
7 study was conducted and the United States-Centres for Disease Control and Prevention for
8 technical support and Nigeria Field Epidemiology and Laboratory Training Programme
9 (NFELTP) for providing financial support.

10 Authors' contributions

11 MOA and AK were involved in the conception, design, and execution of the study. MOA,
12 AK, and NA were involved in the analysis and data interpretation. OA contributed to data
13 interpretation, drafting, formatting and final revision of the manuscript for intellectual
14 content. MOA, OA, and AU reviewed the manuscript for intellectual content. All authors
15 read and agreed to the final version of the manuscript.

16 Data Availability Statement

17 All relevant data to the study are included in the article or uploaded as supplementary
18 information.

19 Funding

20 This work was funded by the United States Centres for Disease Control and Prevention
21 through African Field Epidemiology Network to the Nigeria Field Epidemiology and
22 Laboratory Training Programme (Cooperative Agreement Number: U2GGH001876).

23 Competing interests

24 None declared.

25 References

- 26 1. Harries AD, Murray MB, Jeon CY et al. Defining the research agenda to
27 reduce the joint burden of disease from diabetes mellitus and tuberculosis. *Trop*
28 *Med Int Health*. 2010; 15:659-63.
- 29 2. Sen T, Shashank R, Zarir F. Tuberculosis and Diabetes Mellitus: Merging
30 Epidemics. *J Assoc. Physicians India*. 2009; 57:62-65.

3. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/global_report/en/, accessed 27th May 2020).
4. National Population Commission (NPC) [Nigeria] 2006 Population and Housing Census of the Federal Republic of Nigeria. Abuja, Nigeria: National Population Commission; 2006.
5. WHO Global tuberculosis report 2018. Geneva: World Health Organization; 2018 (https://www.who.int/tb/publications/global_report/en/, accessed 27th May 2020).
6. Golsha R, Rezaei SR, Shafiee A, et al. Pulmonary tuberculosis and some underlying conditions in Golestan Province of Iran, during 2001–2005. *J. Clin. Diag. Res.* 2009; 3(1), 1302–1306.
7. Lönnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. *Soc. Sci. Med.* 2009; 68:2240-2246.
8. International Diabetes Federation. IDF Diabetes Atlas (Internet). 7th edn: 2015. www.diabetesatlas.org (Accessed 6th June 2016).
9. World Health Organization. Global report on diabetes. Diabetes Country profiles (Internet).2016. <https://www.who.int/diabetes/publications/grd-2016/en/> Accessed 6th June 2016.
10. Baghaei P, Marjani M, Javanmard P et al. Diabetes mellitus and tuberculosis facts and controversies. *J Diabetes Metab Disord.* 2013;12:58.
11. Zhou T, Hu Z, Yang S et al. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. *J Diabetes Res.* 2018; 2018:7457269.
12. Jeon CY, Murray, MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. *PLoS Med;* 2008; 5:152.
13. Riza AL, Pearson F, Ugarte-Gil, C et al. Clinical management of concurrent Diabetes and Tuberculosis and the implications for patient services. *Lancet Diabetes Endocrinology;* 2013; 2:740-753.
14. Ogbera AO, Kapur A, Chinenye S et al. Undiagnosed Diabetes Mellitus in Tuberculosis: A Lagos report. *Indian J Endocrinol metab.*2014; 18:475-479.
15. Shittu RO, Kasali FO, Biliaminu SA et al. Prevalence of Diabetes and Pre-diabetes in Oke-Ogun Region of Oyo State, Nigeria. *J Med Res Health Educ.*2017; 1:1.
16. Kibirige D, Ssekitoleko R, Mutebi E et al. Overt diabetes mellitus among newly diagnosed Ugandan tuberculosis patients: a cross-sectional study. *BMC Infect Dis.* 2013; 13:122.
17. Workneh MH, Bjune GA, Yimer SA. Prevalence and Associated Factors of Diabetes Mellitus among Tuberculosis Patients in South-Eastern Amhara Region, Ethiopia: A Cross Sectional Study. *PLoS One.* 2016; 11:1.
18. Chang JT, Dou HY, Yen, CY et al. Effect of type-2 diabetes on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multi drug resistance. *J Formos med. Asbc.* 2011;110: 372-381.

19. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L et al. Association of diabetes and tuberculosis: Impact on treatment and post-treatment outcome. *Thorax*. 2013;68: 214-220.
20. Balakrishna S, Vijayan S, Nair S et al. High diabetes prevalence among tuberculosis cases in Kerala, India. *PLoS One*.2012;7: e46502.
21. Mugusi F, Swai AB, Alberti KG et al. Increased prevalence of Diabetes Mellitus in patients with Pulmonary Tuberculosis in Tanzania. *Tubercle*. 1990; 71: 271-276.
22. Li L, Lin Y, Mi F et al. Screening of patients with tuberculosis for Diabetes Mellitus in China. *Trop Med Int Health*. 2012;17: 1294-301.
23. Dave P, Shah A, Chauhan M et al. Screening patients with tuberculosis for Diabetes Mellitus in Gujarat, India. 2013; 3 (Suppl 1): S29–S33.
24. Naik B, Kumar A MV, Satyanarayana S et al. Is screening for diabetes among tuberculosis patients feasible at the field level? *Public Health Action*. 2013;3 (Suppl 1): S34-S37.
25. Getachew A, Mekonnen S, Alemu S et al. High magnitude of Diabetes Mellitus among Active Pulmonary Tuberculosis Patients in Ethiopia. *British Journal of Medicine & Medical Research*. 2014; 4:862-872.
26. Damtew E, Ali I, Meressa D. Prevalence of Diabetes Mellitus among Active Pulmonary Tuberculosis patients at St Peter specialized Hospital, Addis Ababa, Ethiopia. *World Journal of medical Sciences*. 2014; 1:389-396.
27. Viswanathan V, Kumpatla S, Aravindalochann V et al. Prevalence of Diabetes and Pre-diabetes mellitus and associated risk factors among tuberculosis patients in India. *PLoS One*. 2012;7: e41367.
28. Amare H, Gelaw A, Anagaw B, Gelaw B. Smear positive pulmonary tuberculosis among diabetic patients at the Dessie referral hospital, Northeast Ethiopia. *Infect Dis Poverty*. 2013; 2:6.
29. Reis SB, Gomes T, Locatelli R et al. Treatment outcomes in Tuberculosis patients with diabetes: A polytomous analysis using Brazilian surveillance system. *PLoS One*. 2014;9.7: e100082.
30. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly Detected Pulmonary Tuberculosis Patients in China: A Community Based Cohort Study. *PLoS One*. 2013. 8(12): e82660.
31. Lienhardt C, Fielding K., Sillah JS et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. *Int J Epidemiol* 2005; 34: 914-923.
32. Delgado-Sánchez G, García-García L, Castellanos-Joya M et al. Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000-2012. *PLoS One*.2015;10:e0129312.
33. Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. *Physiol Behav*. 2018; 187:20-23.
34. Ding EL, Song Y, Malik, VS et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2006; 295:1288-1299.

- 1
2
3 1 35. Blaak E. Gender differences in fat metabolism. *Curr Opin Clin Nutr Metab*
4 2 *Care*. 2001; 4:499-502.
5 3
6 3 36. Sharev V, Chodick G, Heyman AD et al. Gender differences in healthcare
7 4 utilization and medical indicators among patients with diabetes. *Public health*.
8 5 2005;119: 45-49.
9 6
10 6 37. Chiu CJ, Wray LA. Gender differences in functional limitations in adults living
11 7 with type 2 diabetes: bio behavioural and psychosocial mediators. *Ann Behav*
12 8 *Med* .2011; 41:71-82.
13 9
14 9 38. International Diabetes Federation Atlas, 6th Edition. International Diabetes
15 10 Federation, 2013. <http://www.idf.org/diabetesatlas>.
16 11
17 11 39. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly
18 12 Detected Pulmonary Tuberculosis Patients in China: A Community Based
19 13 Cohort Study. *PLoS One*. 2013; 8: e82660.
20 14
21 14 40. World Health Organization. 2012. The determinants of health. Health Impact
22 15 Assessment. <https://www.who.int/hia/evidence/doh/en>. Accessed 5 June 2016.
23 16
24 16 41. Strobe M, Schut H, Strobe W. Health outcomes of bereavement. *Lancet*.
25 17 2007;370: 1960-1973.
26 18
27
28 19
29
30
31 20
32
33 21
34
35 22
36
37 23
38
39 24
40
41 25
42
43 26
44
45 27
46
47 28
48
49

50 29 **Figure:** Sampling strategy flow chart

51 30 Oyo central senatorial zone: Akinyele, Egbeda, Ona-ara, Oyo east

52 31 Oyo north senatorial zone: Saki west, Kajola, Iseyin

53 32 Oyo south senatorial zones: Ibadan Northeast, Ibadan Northwest, Ibadan Southeast, Ibadan
54 33 Southwest.
55 34

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure
Sampling strategy flow chart

210x297mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
	(c) Explain how missing data were addressed	Not Applicable (N/A)	
	(d) If applicable, describe analytical methods taking account of sampling strategy	6-7	
	(e) Describe any sensitivity analyses	N/A	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	(Uploaded)
Descriptive data	14*	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10

1			
2	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included
3			
4			
5			
6			(b) Report category boundaries when continuous variables were categorized
7			
8			
9			
10			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
11			
12			
13	Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses
14			
15			
16	Discussion		
17	Key results	18	Summarise key results with reference to study objectives
18			
19			
20	Limitations	19	Discuss limitations of the study, considering sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
21			
22			
23			
24	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
25			
26			
27	Generalisability	21	Discuss the generalisability (external validity) of the study results
28			
29			
30	Other information		
31	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
32			
33			
34			
35			

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Diabetes Mellitus and Its Associated Factors among Tuberculosis Patients Attending Directly Observed Treatment Centres in Oyo State, Nigeria: A cross sectional evaluation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059260.R2
Article Type:	Original research
Date Submitted by the Author:	06-Mar-2022
Complete List of Authors:	Anyanwu, Maureen; African Field Epidemiology Network Nigeria Ajumobi, Olufemi; University of Nevada Reno School of Community Health Sciences Afolabi, Nathanael; University of Ibadan, Department of Epidemiology and Medical Statistics Usman, Aishat; African Field Epidemiology Network Nigeria Kehinde, Aderemi; College of Medicine, University of Ibadan, Department of Medical Microbiology and Parasitology
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Tuberculosis < INFECTIOUS DISEASES, PUBLIC HEALTH, Epidemiology < TROPICAL MEDICINE, Tropical medicine < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **1 Diabetes Mellitus and Its Associated Factors among Tuberculosis**
5 **2 Patients Attending Directly Observed Treatment Centres in Oyo**
6 **3 State, Nigeria: A cross sectional evaluation**
7
8

9
10 4 Maureen O. Anyanwu^{1*}, Olufemi O. Ajumobi², Nathanael B. Afolabi³, Aishat B. Usman¹,
11 5 Aderemi O. Kehinde⁴.

- 12
13 6 1. African Field Epidemiology Network, Nigeria
14 7 2. University of Nevada, Reno School of Community Health Sciences, Nevada, USA.
15 8 3. Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of
16 9 Medicine, University of Ibadan, Nigeria.
17 10 4. Department of Medical Microbiology and Parasitology, Faculty of Basic Medical
18 11 Sciences, College of Medicine, University of Ibadan, Nigeria.
19
20
21
22

23
24 13 *Corresponding author:

25
26 14 Maureen Odochi Anyanwu- Nigeria Field Epidemiology and Laboratory Training
27 15 Programme- African Field Epidemiology Network Nigeria

28
29 16 E mail: maureenanyanwu23@yahoo.com

30
31 17 Postal Code: 900108

32
33 18 Phone number: +234(0)8058290709
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Objective**

3 Diabetes mellitus (DM) and Tuberculosis (TB) comorbidity is evolving into an emerging
4 epidemic globally. In Nigeria, a high burden of both diseases respectively exists with limited
5 information on Tuberculosis-Diabetes Mellitus (TB-DM) comorbidity. We determined the
6 fasting blood glucose (FBG) level among patients with TB and factors associated with TB-
7 DM comorbidity in Oyo State, South-west Nigeria.

8 **Methods**

9 A cross-sectional study was conducted among TB patients aged 15 years and above, who
10 were selected using multistage sampling. Data were collected on patients' biodata,
11 anthropometric measurements and FBG levels using a pretested semi-structured
12 questionnaire. The FBG test was conducted on confirmed Pulmonary TB patients (old and
13 newly diagnosed TB patients) at any stage of anti-tuberculosis treatment. Background
14 characteristics and FBG level were summarized using descriptive statistics and factors
15 associated with TB-DM comorbidity were examined at bivariate and multivariable analyses.

16 **Results**

17 Of the 404 TB patients, 30 (7.4%) had impaired fasting glucose and 32 (7.9%) were
18 diagnosed with diabetes. The mean age of the male and female respondents was 41 (± 14.2)
19 and 36.8 (± 15.0) respectively. Females were more likely than males to have diabetes (10.6%
20 vs. 6.3%). Median FBG level for the patients was 88 (Interquartile range: Q1: 99, Q3:79)
21 mg/dl. Age, marital status, and educational level were not associated with TB-DM co-
22 morbidity. In the multivariable model, only normal body mass index was independently and
23 significantly associated with diabetes.

24 **Conclusion**

25 Tuberculosis-Diabetes Mellitus was prevalent among the studied population in South-west
26 Nigeria. We recommend the integration of DM screening within the continuum of care for
27 TB management.

28
29 **Keywords:** Tuberculosis-Diabetes Mellitus comorbidity, Hyperglycaemia, Nigeria.

Article summary:**• Strengths and limitations of the study**

- Our study used a hospital design that enabled access to TB patients in a clinic setting and this approach is a potential opportunity for implementing concurrent regular routine screening and clinical management, lifestyle modification, and follow-up for TB-DM comorbidity.
- Alcohol consumption and smoking are culturally undesirable behaviours and thus, they might have been underreported by participants.
- The outcomes of TB management in TB-DM comorbid individuals such as cure rate, treatment success rate, or death could not be ascertained in our study, which was a cross-sectional evaluation.

er review only

1 Introduction

2 Tuberculosis remains a major global infectious disease that causes morbidity and death. Low-
3 and middle-income countries harbor about 95% and 75% of tuberculosis (TB) and diabetes
4 mellitus (DM) patients respectively.^{1 2} Incident cases of TB were reported to be the highest
5 among people with impaired immunity, human immunodeficiency virus (HIV) infection or
6 DM.² In 2018, an estimated 10.0 million individuals were newly diagnosed with TB, 1.2
7 million and 250,000 people died among HIV-negative and HIV- positive people respectively,
8 of which Africa accounted for 24%.³ Nigeria belongs to one of the 30 high-burden TB
9 countries worldwide.³ In 2018, Nigeria was among the top 8 high TB burden countries, with
10 an estimated 429,000 new TB cases (219 per 100,000 population), and mortality of 123,000
11 (64 per 100,000 population) excluding TB-HIV cases.³ Nigeria, with a population of more
12 than 190 million,⁴ has the highest burden of the disease globally with a total TB incidence of
13 418,000 (219 per 100,000).⁵

14 Despite the success of the TB control strategies, TB persists in several parts of the world.⁵
15 This signifies the need to intensify control efforts that identify and address the individual and
16 social determinants of the disease. Structural factors, (e.g., suboptimal case detection and
17 non-adherence to therapy), and host-level factors, (e.g., HIV and diabetes mellitus [DM]) that
18 increase vulnerability to active TB are major challenges to TB control.^{6 7}

19 In 2019, according to International Diabetes Federation (IDF),⁸ there were an estimated 463.0
20 million and 19.4 million people with DM globally and in Africa respectively. By 2030, it is
21 projected that 28.6 million adults in Africa will have DM.⁸ In 2019, an estimated 4.2 million
22 (20-79 years) and more than 366,200 deaths globally and in Africa respectively, could be
23 attributed to DM.⁸ In Nigeria, the prevalence of DM in the general population was 4.3%, and
24 2% of total death in all ages was caused by the disease.⁹

25 Many studies conducted in different parts of the globe have revealed a bidirectional
26 association between TB and DM.¹⁰ This close link is striking in developing countries, where
27 TB is endemic and the burden of DM is high and increasing,¹⁰ including Nigeria.

28 DM directly impairs innate and adaptive immune responses that are necessary to combat the
29 progression from infection to clinical diseases.¹¹ Diabetes mellitus is a known risk factor for
30 tuberculosis,¹² and is associated with poorer tuberculosis outcomes, while tuberculosis is
31 associated with regressing glycaemic control.¹³ Hence, it is advantageous to screen and
32 identify undiagnosed DM among TB patients and then, offer glycaemic control, in order to
33 prevent or delay diabetes-related complications and improve TB treatment outcomes
34 accordingly.

35 Despite the evidence which supports DM as a risk factor for TB, few studies have been
36 documented in Nigeria. No study has been conducted and reported in Oyo State to the best of
37 our knowledge. This study aimed at determining the prevalence of DM and its associated
38 factors among patients attending Directly Observed Treatment Centres (DOTS) in Oyo State,
39 South-west, Nigeria.

40

1 **Methods**

2 **Study setting**

3 Oyo State is in South-west Nigeria, the most populous country in sub-Saharan Africa. It has
4 33 Local Government Areas (LGAs) distributed over its three (3) senatorial districts. The
5 State has 244 Directly Observed Treatment Centre-Short course (DOTS) centres across the
6 33 LGAs in Oyo State, comprising 200 public and 44 private DOTS centres. All the LGAs
7 have several DOTS centres and are supported by Damien Foundation, Belgium, a leading
8 Non-Governmental Organization (NGO) with a focus on effective TB management and
9 control. Overall, there were 1,743 TB patients on treatment in all the DOTS clinics in Oyo
10 State at the time of the study.

11 Sputum smear microscopy was the prevailing primary test for the diagnosis of pulmonary
12 tuberculosis (PTB) in Nigeria. Smears may be prepared directly from clinical specimens or
13 from concentrated preparations using Ziehl-Nielsen staining or Fluorescent Auramine
14 staining technique to observe acid-fast bacilli. A sputum result is positive if at least one
15 tubercle bacillus (acid-fast/fluorescent) is detected on one or more sputum smears. The
16 glycoated haemoglobin test is used to both diagnose DM and assess control in DM.

17 **Study design**

18 A cross-sectional facility-based study was conducted among consenting TB patients aged
19 15 years and above attending DOTS centres in Oyo State. Participants were systematically
20 selected in each DOTS centre. There was no age-cut off for the study and no participant
21 under the age of 15 years was selected. However, parents/guardians gave consent for
22 participants who were between the ages of 15 and 17 years old. Pregnant TB patients and
23 extra-pulmonary TB cases were excluded from the study. The fasting blood glucose level was
24 ascertained for confirmed old and newly diagnosed pulmonary TB (PTB) patients both at any
25 stage of anti-tuberculosis treatment.

26 **Sampling technique**

27 A stratified sampling approach was used to select the study participants in the first stage. The
28 LGAs were proportionally allocated to the 3 senatorial zones of the State. Eleven of the 33
29 LGAs in Oyo State, Nigeria were selected for the study, using simple random sampling by
30 balloting in each of the 3 senatorial zones, namely, Oyo central (4 out of 11 LGAs were
31 selected), Oyo north (3 out of 13 LGAs were selected) and Oyo south (4 out of 9 LGAs were
32 selected) of the State. In the second stage, one DOTS centre was selected using simple
33 random sampling in each of the 11 LGAs selected, and 404 patients were systematically
34 selected, proportional to the size in each of the 11 DOTS centres selected. (Figure).

35 The minimum sample size of 364 was calculated with the formula for estimating a single
36 population proportion ($n = Z^2 p(1 - p)/d^2$), 12.3% proportion,¹⁴ for 0.05 precision and Z of
37 1.96. The final sample size was 404 TB patients after correcting for a finite population and
38 accounting for a 10% non-response rate.

39

1 **Data collection**

2 The study instrument was adapted from an earlier study. Trained data collectors administered
3 the pre-tested interviewer-administered semi-structured questionnaire to the selected TB
4 patients to collect information on respondents' socio-demographic characteristics, lifestyle
5 factors, clinical characteristics, and socio-economic status.

6 Data on past medical history and duration of their treatment on anti-TB drugs were extracted
7 from patients' clinical records.

8 Anthropometric measures: height, weight and waist circumference using standard procedures.
9 Body Mass Index (BMI, kg/m²) were obtained using standard procedures: BMI (kg/m²) was
10 calculated as Weight (kg)/Height (m²). Blood pressure was measured in millimeters of
11 mercury (mm Hg) using a digital BP measurement device.

12 All participants were tested for DM, irrespective of prior diabetes status. Screening for DM
13 among the respondents was done by Fasting Blood Sugar (FBS) test, using an electronic
14 glucometer and test strips (ACCU-CHEK Active by Roche), in the morning at the respective
15 DOTS centres, in respondents who have fasted for at least 8 hours overnight. The DM status
16 was assessed in line with the WHO recommendation for the diagnostic criteria for diabetes
17 and intermediate hyperglycaemia.⁹ (110mg/dl to 125mg/dl – prediabetic/impaired fasting
18 glucose; (≥126mg/dl – diabetic/fasting plasma glucose).

19 TB patients who were diagnosed with DM were referred to DM clinics situated in Oyo State,
20 Nigeria for prompt and appropriate management.

21 **Data processing and analysis**

22 The dependent variable is diabetes status (Fasting Blood Glucose level). The independent
23 variables included age, sex, residence, education, marital status, occupation, HIV status,
24 smoking, BMI, drinking of alcohol, family history of diabetes, physical activity (exercise)
25 and socio-economic status. The main outcome variables were proportions of patients with a
26 diagnosis of TB-DM and TB without DM (TB-DM co-infection status), and patients with
27 Impaired Fasting Glucose were not included in the non-diabetic group for the analysis.
28 Variables were summarized with descriptive statistics. Bivariate analysis using Pearson's chi-
29 squared test or Fisher's Exact Test was conducted to determine the relationship between the
30 dependent variable and other independent variables. Predictors of the outcome variable (DM)
31 were identified with a multiple binary logistic regression analysis. Covariates selected for the
32 adjusted model were predictive at 10% level of significance and were carried over to the
33 adjusted model. The SES definitions were computed through principal component analysis
34 which aggregates possession of economic household items and divides it into quintiles. Each
35 respondent was given a score based on the number and kinds of consumer goods owned or
36 services enjoyed, ranging from radio, television, mobile telephone, refrigerator, cable TV,
37 generating set, air conditioner, computer, electric iron, fan, motorcycle, car/truck, land
38 ownership, house ownership, livestock/other farm animals/poultry and availability of
39 electricity. These scores were derived through principal component analysis and using the
40 first factor that has the highest proportion of information explained (25%) to rank each

1 participant by their score. The score was then divided into three equal categories, each
 2 comprising 33% of the population. In this case, SES was categorized into three quintiles.
 3 Results were presented at the 5% alpha significant level. Analysis was performed using Epi
 4 info version 7 and SPSS Statistical Software.

5 Ethical consideration

	Diabetics n (%)	Non-diabetics n (%)	Total n (%)	P-value
Sex				
Male	16(6.3)	237(93.7)	253(62.6)	0.124
Female	16(10.6)	135(89.4)	151(37.4)	
Age				
15-24	1(1.7)	57(98.3)	58(14.4)	

6 Ethical clearance was obtained from the Ethics Committee of the Oyo State Ministry of
 7 Health (reference number: AD 13/479/277, date: 15 November 2016). Informed consent was
 8 obtained from the study participants and guardians- for participants below the age of 18
 9 years. Confidentiality of information obtained was maintained; data were de-identified.

10 Patient and Public Involvement

11 Patients and the public were not involved in the design of this study. However, patients
 12 served as study participants and were recruited after obtaining informed consent.

13 Results

14 We approached a total of 426 selected patients, replaced immediately those who refused to
 15 participate in the study (n =22) until we attained our sample size of 404 (response rate
 16 =94.8% (404/426). The overall prevalence of TB-DM comorbidity was 7.9% (32/404) [95%
 17 CI: 5.7- 10.9]. The proportion of IFG TB patients was 7.4% (30/404). The mean age of the
 18 male and female respondents was 41 (\pm 14.2) and 36.8 (\pm 15.0) respectively. There was a
 19 female preponderance for TB-DM comorbidity (Table 1). There was a female preponderance
 20 for TB-DM comorbidity. 22% of these individuals (n=9) had no formal education (Table 1).
 21 TB-DM comorbidity among those in poor (10.5%) and average (7.4%) socio-economic status
 22 (SES) were higher than the rich (Table 1). Compared to underweight participants, participants
 23 with normal body mass index had 129% higher odds of being diabetic and overweight
 24 patients with TB-DM comorbidity had 81% higher odds of being diabetic, but these were not
 25 statistically significant (Table 2).

26 Age (aOR: 2.28, 95%CI: 0.91, 5.74) and marital relationships ([being married, aOR: 2.23, 95%
 27 CI: 0.45 – 10.97] and being separated/divorced/widowed, aOR: 3.80, 95% CI: 0.48 – 30.13]) were
 28 not significant predictors of being a diabetic TB patient. In the multivariate model, only normal
 29 body mass index was independently and significantly associated with diabetes (Table 3).

25-44	11(5.1)	203(94.9)	214(53.0)	0.000
45-64	12(12.2)	86(87.8)	98(24.3)	
≥65	8(23.5)	26(76.5)	34(8.4)	
Religion				
Christian	9(8.3)	99(91.7)	108(26.7)	0.853
Muslim	23(7.8)	273(92.2)	296(73.3)	
Education level				
No formal Education	9(22.0)	32(78.0)	41(10.0)	OR (95% C.I) 0.02
Primary school	11(9.7)	102(90.3)	113(28.0)	
Secondary school	10(4.5)	205(95.3)	215(53.2)	
University/ Higher education	2(5.7)	32(94.3)	35(8.7)	
Marital status				
Single	2(2.4)	82(97.6)	84(21.0)	0.025
Married	27(8.8)	279(91.2)	306(75.4)	
Divorced/Separated/Widowed	3(21.4)	11(78.6)	14(3.5)	
Place of residence				
Urban	24(8.2)	269(91.8)	293(72.5)	0.744
Rural	8(7.2)	103(92.8)	111(24.5)	
Occupation				
Govt/Private employed	2(5.9)	32(94.1)	34(8.4)	0.296
Self-employed	25(8.3)	277(91.7)	302(74.8)	
Student	1(2.4)	40(97.6)	41(10.1)	
Unemployed	4(14.8)	23(85.2)	27(6.7)	
Average monthly income (Naira)				
< 18,000	15(6.6)	211(93.4)	226(55.9)	0.202
18,000-50,000	9(7.6)	109(92.4)	118(29.2)	
> 51,000	8(13.3)	52(86.7)	60(14.9)	
Ethnicity				
Yoruba	31(7.7)	360(92.1)	391(96.8)	0.975
Others (Hausa, Ibo, etc)	1(0.2)	12(92.3)	13(3.2)	
Socioeconomic status				
Poor	14(10.5)	120(89.6)	134(33.2)	0.381
Average	10(7.4)	126(92.7)	136(33.7)	
Rich	8(6.0)	126(94.0)	134(33.2)	

Table 1: Socio-demographic characteristics of diabetic and non-diabetic Tuberculosis patients (n=404)

Table 2: Factors associated with diabetes status among TB patients

Told in the past that you have DM?			
Yes	19(82.6)	23	134.46 (40.02 – 451.73)
No	13(3.4)	381	1.00
Smoking			
Yes	9(8.5)	106	1.11 (0.49 – 2.48)
No	23(8.3)	276	1.00
Adjusted Odds Ratio (95% CI)			
Characteristic	p-value		
Yes	9(7.0)	128	0.83 (0.37 – 1.85)
No	23(8.3)	276	1.00
Duration of TB treatment			
< 1 month	26(8.3)	314	0.79 (0.32 – 1.98)
> 1 month	6(7.5)	90	1.00
Do you take any other stimulant?			
Yes	3(7.0)	43	0.86 (0.25 – 2.95)
No	29(8.0)	361	1.00
Habit of exercise			
Yes	4(5.3)	75	0.61 (0.21 – 1.78)
No	28(8.5)	329	1.00
BMI (Kg/m²)			
Underweight	8(4.8)	167	1.00
Normal	22(10.3)	213	2.29 (0.99 – 5.28)
Overweight/Obese	2(8.3)	24	1.81 (0.36 – 9.06)
Family History of Diabetes Mellitus			
Yes	1(50.0)	2	12.00 (0.73 – 196.00)
No	31(7.7)	402	1.00
Close contact with TB patient			
Yes	2(3.8)	53	0.42 (0.10 – 1.81)
No	30(8.6)	351	1.00

Table 3: Multivariable analysis of the predictors of DM

Age group		
<40 (ref)	1.00	
40+	2.28 (0.91, 5.74)	0.080
Educational level		
No formal education	2.72 (0.49 – 15.08)	0.252
Primary school	1.06 (0.21 - 5.41)	0.945
Secondary school	0.60 (0.12 - 3.00)	0.532
University/higher education (ref)	1.00	
Marital Status		
Single (ref)	1.00	
Married	2.23 (0.45 – 10.97)	0.323
Divorced/Separated/Widowed	3.80 (0.48 – 30.13)	0.206
BMI (Kg/m²)		
Underweight (ref)	1.00	
Normal	2.91 (1.18-7.14)	0.020
Overweight/Obese	1.75 (0.33 – 9.39)	0.514

*=statistically significant at $\leq 5\%$

Discussion

Our study revealed that the prevalence of DM among diagnosed TB patients was 7.9%. There was a high proportion of TB-DM comorbidity among women, older persons (at least 44 years), persons with informal education, and those in a single relationship (Divorced/Separated/Widowed). Although, the above-mentioned factors were not shown to be of significant risk at the multivariate level. Screening for DM in TB patients could improve DM

1
2
3 1 case detection and early initiation of treatment, education of patients and correction of
4 2 hyperglycaemia, which potentially could have positive effects on the outcome of TB
5 3 treatment.
6
7

8 4 In Nigeria, the most recent prevalence of DM in the general population was 4.3%.⁹ This is
9 5 similar to 4.6% as reported by Shittu et al in a similar population in the Oke-Ogun geo-
10 6 political zone of Oyo State, Nigeria.¹⁵ The prevalence of DM in this study is quite alarming
11 7 (7.9%), it is comparable to the studies conducted in Uganda (8.5%),¹⁶ and Ethiopia (8.3%).¹⁷
12 8 However, the current findings were lower than what was reported from Taiwan (29.5%),¹⁸
13 9 Southern-Mexico (29.3%),¹⁹ Kerala-India (44%),²⁰ Lagos, Nigeria (12.3%).¹⁴ The reported
14 10 finding in Tanzania was lower (4%).²¹ Reasons for the observed variation in the prevalence
15 11 might be related to differences in background between populations (rural and urban settings)
16 12 and screening methods (RBS, FBS and Oral Glucose Tolerance Test etc.) used in DM
17 13 diagnosis.
18
19

20 14 The prevalence of IFG in this study was 7.4%. This finding is similar to the study done in
21 15 Taian, Dingxi, Jinan, Shijiazhuang, Guiyang- China (7.8%),²² Gujarat-India (7%),²³ higher
22 16 than Kolar-India (3.1%),²⁴ but lower than the study findings from Gondar-Ethiopia (29.6%),
23 17 Addis Ababa-Ethiopia (26.7%) and Tamil Nadu-India (24.5%),²⁵⁻²⁷ respectively. Individuals
24 18 with impaired fasting glucose (IFG) are at high risk of progressing to type 2 DM, although
25 19 this is not inevitable,⁹ and this may go further to indicate an increased risk of DM in the
26 20 future in Nigeria. The observed prevalence of DM and IFG in our study pose threats to gains
27 21 made in TB control which necessitates an integrated health services approach to effectively
28 22 address the burden of the two diseases.
29
30

31 23 The TB-DM comorbidity demonstrated an association with age, although older age (40+
32 24 years) was not an independent predictor of developing DM in TB patients). The occurrence
33 25 of DM in older people has been reported in studies done in Addis Ababa–Ethiopia,²⁶ Dessie-
34 26 Ethiopia,²⁸ Kerala-India,²⁰ Tamil Nadu–India,²⁷ Brazil,²⁹ Southern-Mexico,¹⁹ and China.³⁰
35 27 This may be because DM is an age-related illness that occurs in persons above 40 years.
36 28 Earlier studies which determined the risk factors for TB also corroborated this detail.³¹ Old
37 29 age is related to immunosuppression and is one of the risk factors for both TB and DM.^{8,2} In
38 30 Nigeria, for example, the risk of developing DM increases three to four folds after the age of
39 31 44 years,¹⁵ a consistent finding with this study where age group > 44 years had a higher
40 32 proportion of TB with DM comorbidity. This strongly suggests that the health care system in
41 33 Nigeria should improve its content and delivery of services with respect to older age groups.
42
43

44 34 A slightly higher preponderance of TB-DM comorbidity among females than males in this
45 35 study is similar to those found in studies done in Ethiopia,¹⁷ and Mexico.³² The prevalence
46 36 and complication of diabetes are more pronounced in females than males as a result of
47 37 gender-associated adiposity.³³ Unlike for men, increased androgen levels induce insulin
48 38 resistance in women,³³ and increase the risk of type 2 diabetes and cardiovascular diseases.³⁴
49 39 Women have a higher percentage of body fat and more often develop peripheral adiposity,
50 40 whereas men accumulate fat centrally.³⁵ Women generally have poorer glycemic control.^{36,37}
51 41 The health system in Nigeria should be geared towards ensuring that concerned females are
52
53
54
55
56
57
58
59
60

1
2
3 1 duly educated on preventive measures against DM and encouraged to utilise available health
4 2 services to halt the trend of DM among Nigerian women.

5
6 3 Positive family history is a known risk factor for DM.³⁸ However, there was no significant
7 4 association with DM among TB patients who have a family history/genetic predisposition to
8 5 DM. This finding is in contrast with studies conducted in Tamil Nadu-India and China.^{27 39}

9
10 6 Tuberculosis is a disease of poverty. In our study, two-thirds of the respondents were of low
11 7 and average socioeconomic status. This portends a lack of adequate resources to a large
12 8 proportion of the participants and could be a challenge for persons living with diabetes in
13 9 Nigeria. Therefore, these should be considered in the management of the disease which
14 10 comes at a huge personal out-of-pocket cost.

15
16 11 Most of the diabetic respondents (22.0%) had no formal education compared to those with
17 12 higher level of education. Many factors are shown to affect the health of individuals and
18 13 communities, namely, low educational level, which relates to poor health, higher stress level
19 14 and lower self-esteem.⁴⁰ Educational programmes that embody and emphasize awareness of
20 15 DM and its preventative measures and complications, self-care management behaviour
21 16 (adherence to diabetic medications, healthy diet, regular exercise and follow up should be
22 17 effectively propagated across all levels). The death of a spouse currently ranks as the life-
23 18 event needing the most intense social readjustment and poses health risks.⁴¹

24 19 **Strengths and limitation**

25 20 This is one of the few studies on TB-DM comorbidity conducted and documented in Nigeria,
26 21 at the time of the study. The findings are generalizable to similar settings in Nigeria and other
27 22 low-and-middle-income countries. Alcohol consumption and smoking are culturally
28 23 undesirable behaviours and, thus, they might have been underreported by participants. The
29 24 outcomes of TB management in TB-DM comorbid individuals such as cure rate, treatment
30 25 success rate or death could not be ascertained in our study, as it is a cross-sectional
31 26 evaluation.

32 27 **Conclusion**

33 28 There was a high prevalence of DM among TB patients. Age, marital status, and educational
34 29 level were not associated with TB-DM co-morbidity. Although not revealed to be significant
35 30 risk factors at the multivariate level, a current single relationship from a previous married
36 31 relationship; that is, being divorced, separated, or widowed could pose potential health risks.
37 32 Those in a married spousal relationship tend to benefit from social support towards adhering
38 33 to a healthy behavioural lifestyle. Hence, we recommend that physicians should also be
39 34 aware of possible long-term health risks emerging after widowhood such as changes in
40 35 lifestyle, diet, and adiposity, which may be remedied by attention to healthy behaviour.

41
42
43 36 We hope that data obtained would be used to inform a new holistic national treatment
44 37 guideline for TB, inclusive of routine screening for DM and active management of the
45 38 glycaemia in those found in TB-DM co-morbid individuals. These would result in improved
46 39 treatment outcomes and management in PTB patients.

1 Patient and Public Involvement

2 Patients and the public were not involved in the design of this study. However, patients
3 served as study participants and were recruited after obtaining an informed consent.
4

5 Acknowledgements

6 We wish to acknowledge Dr Anthonia Ogbera for sharing the study instrument, adapted for
7 this study, responsible health facility staff of the respective healthcare centres where this
8 study was conducted and the United States-Centres for Disease Control and Prevention for
9 technical support and Nigeria Field Epidemiology and Laboratory Training Programme
10 (NFELTP) for providing financial support. We would like to thank Waleed Jami, a PhD
11 candidate, Interdisciplinary Social Psychology programme, University of Nevada, Reno,
12 United States for copyediting the manuscript.

13 Authors' contributions

14 MOA and AK were involved in the conception, design, and execution of the study. MOA,
15 AK, and NA were involved in the analysis and data interpretation. OA contributed to data
16 interpretation, drafting, formatting and final revision of the manuscript for intellectual
17 content. MOA, OA, and AU reviewed the manuscript for intellectual content. All authors
18 read and agreed to the final version of the manuscript.

19 Data Availability Statement

20 All relevant data to the study are included in the article or uploaded as supplementary
21 information.

22 Funding

23 This work was funded by the United States Centres for Disease Control and Prevention
24 through African Field Epidemiology Network to the Nigeria Field Epidemiology and
25 Laboratory Training Programme (Cooperative Agreement Number: U2GGH001876).

26 Competing interests

27 None declared.
28
29
30

31 References

- 32 1. Harries AD, Murray MB, Jeon CY et al. Defining the research agenda to
33 reduce the joint burden of disease from diabetes mellitus and tuberculosis. *Trop*
34 *Med Int Health*. 2010; 15:659-63.

- 1
- 2
- 3 1 2. Sen T, Shashank R, Zarir F. Tuberculosis and Diabetes Mellitus: Merging
- 4 2 Epidemics. *J Assoc. Physicians India*. 2009; 57:62-65.
- 5 3
- 6 3 3. Global tuberculosis report 2019. Geneva: World Health Organization; 2019
- 7 4 (https://www.who.int/tb/publications/global_report/en/, accessed 27th May
- 8 5 2020).
- 9 6
- 10 6 4. National Population Commission (NPC) [Nigeria] 2006 Population and
- 11 7 Housing Census of the Federal Republic of Nigeria. Abuja, Nigeria: National
- 12 8 Population Commission; 2006.
- 13 9
- 14 9 5. WHO Global tuberculosis report 2018. Geneva: World Health Organization;
- 15 10 2018 (https://www.who.int/tb/publications/global_report/en/, accessed 27th
- 16 11 May 2020).
- 17 12
- 18 12 6. Golsha R, Rezaei SR, Shafiee A, et al. Pulmonary tuberculosis, and some
- 19 13 underlying conditions in Golestan Province of Iran, during 2001–2005. *J. Clin.*
- 20 14 *Diag. Res*. 2009; 3(1), 1302–1306.
- 21 15
- 22 15 7. Lönnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis
- 23 16 epidemics: the role of risk factors and social determinants. *Soc. Sci. Med* .2009;
- 24 17 68:2240-2246.
- 25 18
- 26 18 8. International Diabetes Federation. IDF Diabetes Atlas (Internet). 7th
- 27 19 edn: 2015. www.diabetesatlas.org (Accessed 6th June 2016).
- 28 20
- 29 20 9. World Health Organization. Global report on diabetes. Diabetes Country
- 30 21 profiles (Internet).2016. [https://www.who.int/diabetes/publications/grd-](https://www.who.int/diabetes/publications/grd-2016/en/)
- 31 22 [2016/en/](https://www.who.int/diabetes/publications/grd-2016/en/) Accessed 6th June 2016.
- 32 23
- 33 23 10. Baghaei P, Marjani M, Javanmard P et al. Diabetes mellitus and tuberculosis
- 34 24 facts and controversies. *J Diabetes Metab Disord*. 2013;12:58.
- 35 25
- 36 25 11. Zhou T, Hu Z, Yang S et al. Role of Adaptive and Innate Immunity in Type 2
- 37 26 Diabetes Mellitus. *J Diabetes Res*. 2018; 2018:7457269.
- 38 27
- 39 27 12. Jeon CY, Murray, MB. Diabetes Mellitus Increases the Risk of Active
- 40 28 Tuberculosis: A Systematic Review of 13 Observational Studies. *PLoS Med*;
- 41 29 2008; 5:152.
- 42 30
- 43 30 13. Riza AL, Pearson F, Ugarte-Gil, C et al. Clinical management of concurrent
- 44 31 Diabetes and Tuberculosis and the implications for patient services. *Lancet*
- 45 32 *Diabetes Endocrinology*; 2013; 2:740-753.
- 46 33
- 47 33 14. Ogbera AO, Kapur A, Chinenye S et al. Undiagnosed Diabetes Mellitus in
- 48 34 Tuberculosis: A lagos report. *Indian J Endocrinol metab*.2014; 18:475-479.
- 49 35
- 50 35 15. Shittu RO, Kasali FO, Biliaminu SA et al. Prevalence of Diabetes and Pre-
- 51 36 diabetes in Oke-Ogun Region of Oyo State, Nigeria. *J Med Res Health*
- 52 37 *Educ*.2017; 1:1.
- 53 38
- 54 38 16. Kibirige D, Ssekitoleko R, Mutebi E et al. Overt diabetes mellitus among
- 55 39 newly diagnosed Ugandan tuberculosis patients: a cross-sectional study. *BMC*
- 56 40 *Infect Dis*. 2013; 13:122.
- 57 41
- 58 41 17. Workneh MH, Bjune GA, Yimer SA. Prevalence and Associated Factors of
- 59 42 Diabetes Mellitus among Tuberculosis Patients in South-Eastern Amhara
- 60 43 Region, Ethiopia: A Cross Sectional Study. *PLoS One*. 2016; 11:1.
- 44 44
- 45 44 18. Chang JT, Dou HY, Yen, CY et al. Effect of type-2 diabetes on the clinical
- 45 45 severity and treatment outcome in patients with pulmonary tuberculosis: a

- potential role in the emergence of multi drug resistance. *J Formos med. Asbc.* 2011;110: 372-381.
19. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L et al. Association of diabetes and tuberculosis: Impact on treatment and post-treatment outcome. *Thorax.* 2013;68: 214-220.
20. Balakrishna S, Vijayan S, Nair S et al. High diabetes prevalence among tuberculosis cases in Kerala, India. *PLoS One.*2012;7: e46502.
21. Mugusi F, Swai AB, Alberti KG et al. Increased prevalence of Diabetes Mellitus in patients with Pulmonary Tuberculosis in Tanzania. *Tubercle.* 1990; 71: 271-276.
22. Li L, Lin Y, Mi F et al. Screening of patients with tuberculosis for Diabetes Mellitus in China. *Trop Med Int Health.* 2012;17: 1294-301.
23. Dave P, Shah A, Chauhan M et al. Screening patients with tuberculosis for Diabetes Mellitus in Gujarat, India. 2013; 3 (Suppl 1): S29–S33.
24. Naik B, Kumar A MV, Satyanarayana S et al. Is screening for diabetes among tuberculosis patients feasible at the field level? *Public Health Action.* 2013;3 (Suppl 1): S34-S37.
25. Getachew A, Mekonnen S, Alemu S et al. High magnitude of Diabetes Mellitus among Active Pulmonary Tuberculosis Patients in Ethiopia. *British Journal of Medicine & Medical Research.* 2014; 4:862-872.
26. Damtew E, Ali I, Meressa D. Prevalence of Diabetes Mellitus among Active Pulmonary Tuberculosis patients at St. Peter specialized Hospital, Addis Ababa, Ethiopia. *World Journal of medical Sciences.* 2014; 1:389-396.
27. Viswanathan V, Kumpatla S, Aravindalochann V et al. Prevalence of Diabetes and Pre-diabetes mellitus and associated risk factors among tuberculosis patients in India. *PLoS One.* 2012;7: e41367.
28. Amare H, Gelaw A, Anagaw B, Gelaw B. Smear positive pulmonary tuberculosis among diabetic patients at the Dessie referral hospital, Northeast Ethiopia. *Infect Dis Poverty.* 2013; 2:6.
29. Reis SB, Gomes T, Locatelli R et al. Treatment outcomes in Tuberculosis patients with diabetes: A polytomous analysis using Brazilian surveillance system. *PLoS One.* 2014;9.7: e100082.
30. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly Detected Pulmonary Tuberculosis Patients in China: A Community Based Cohort Study. *PLoS One.* 2013. 8(12): e82660.
31. Lienhardt C, Fielding K., Sillah JS et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. *Int J Epidemiol* 2005; 34: 914-923.
32. Delgado-Sánchez G, García-García L, Castellanos-Joya M et al. Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000-2012. *PLoS One.*2015;10:e0129312.
33. Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. *Physiol Behav.* 2018; 187:20-23.

- 1
2
3 1 34. Ding EL, Song Y, Malik, VS et al. Sex differences of endogenous sex
4 2 hormones and risk of type 2 diabetes: a systematic review and meta-analysis.
5 3 *JAMA*. 2006; 295:1288-1299.
6 4
7 5 35. Blaak E. Gender differences in fat metabolism. *Curr Opin Clin Nutr Metab*
8 6 *Care*. 2001; 4:499-502.
9 7
10 8 36. Sharev V, Chodick G, Heyman AD et al. Gender differences in healthcare
11 9 utilization and medical indicators among patients with diabetes. *Public health*.
12 10 2005;119: 45-49.
13 11
14 12 37. Chiu CJ, Wray LA. Gender differences in functional limitations in adults living
15 13 with type 2 diabetes: bio behavioural and psychosocial mediators. *Ann Behav*
16 14 *Med* .2011; 41:71-82.
17 15
18 16 38. International Diabetes Federation Atlas, 6th Edition. International Diabetes
19 17 Federation, 2013. <http://www.idf.org/diabetesatlas>.
20 18
21 19 39. Wang Q, Ma A, Han X, et al. Prevalence of Type 2 Diabetes among Newly
22 20 Detected Pulmonary Tuberculosis Patients in China: A Community Based
23 21 Cohort Study. *PLoS One*. 2013; 8: e82660.
24 22
25 23 40. World Health Organization. 2012. The determinants of health. Health Impact
26 24 Assessment. <https://www.who.int/hia/evidence/doh/en>. Accessed 5 June 2016.
27 25
28 26 41. Strobe M, Schut H, Strobe W. Health outcomes of bereavement. *Lancet*.
29 27 2007;370: 1960-1973.
30 28
31 29
32 30
33 31
34 32
35 33
36 34
37 35
38 36
39 37
40 38
41 39
42 40
43 41
44 42
45 43
46 44
47 45
48 46
49 47
50 48
51 49
52 50
53 51
54 52
55 53
56 54
57 55
58 56
59 57
60 58

32 **Figure:** Sampling strategy flow chart

33 Oyo central senatorial zone: Akinyele, Egbeda, Ona-ara, Oyo east

34 Oyo north senatorial zone: Saki west, Kajola, Iseyin

1
2
3 1 Oyo south senatorial zones: Ibadan Northeast, Ibadan Northwest, Ibadan Southeast, Ibadan
4 2 Southwest.
5
6 3
7
8 4
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure
Sampling strategy flow chart

210x297mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
	(c) Explain how missing data were addressed	Not Applicable (N/A)	
	(d) If applicable, describe analytical methods taking account of sampling strategy	6-7	
	(e) Describe any sensitivity analyses	N/A	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	(Uploaded)
Descriptive data	14*	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, considering sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.